



Published in final edited form as:

J Exp Med. 2026 June 01; 223(6): . doi:10.1084/jem.20252632.

LINGO4 coordinates ILC3-intrinsic IL-22 production and microbiota-mediated ILC3 homeostasis

José L. Fachi^{1,*,}, Tihana Trsan^{1,#}, Cristiane Sécca¹, Sarah de Oliveira^{1,2}, Vinícius R. Rodvalho³, Patrick Fernandes Rodrigues¹, Wandy L. Beatty⁴, Raki Sudan¹, Shitong Wu¹, Bishan Bhattarai¹, Santosh K. Panda¹, Marina Cella¹, Susan Gilfillan¹, Marco Colonna^{1,*}

¹Department of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO 63110, USA

²Department of Genetics, Evolution, Microbiology, and Immunology, Institute of Biology, University of Campinas, Campinas, SP 13083-862, Brazil

³Bioinformatics Laboratory, National Laboratory for Scientific Computation (LNCC), Petrópolis, RJ 25651-075, Brazil

⁴Department of Molecular Microbiology, Washington University in St. Louis, School of Medicine, Saint Louis, MO 63110, USA

Abstract

LINGO4 is a leucine-rich repeat and immunoglobulin-like domain-containing transmembrane protein encoded immediately adjacent to *Rorc*, the gene for ROR γ t, raising the possibility that it contributes to the biology of ROR γ t⁺ lymphocytes. However, its impact on these cells and resistance to enteric infections has remained unknown. Here, we identify LINGO4 as a critical regulator of group 3 innate lymphoid cells (ILC3s). *Lingo4*^{-/-} ILC3s exhibit a profound, cell-intrinsic defect in IL-22 production linked to impaired STAT3 activation, mitochondrial dysfunction, elevated reactive oxygen species, and increased apoptosis. In vivo, *Lingo4* deficiency also drives a dysbiotic gut microbiota, resulting in an additional, microbiota-dependent loss of ILC3s. These combined defects increase susceptibility to *C. difficile* and *C. rodentium*, whereas IL-22 reduction in *Lingo4*^{-/-} mice confers protection against *S. Typhimurium*. Immunoprecipitation of tagged LINGO4 reveals interaction networks enriched in mitochondrial pathways, providing mechanistic insight into its role in ILC3 metabolic fitness and intestinal immunity.

summary statement:

*Correspondence: fachi@wustl.edu (J.L.F.); mcolonna@wustl.edu (M. Colonna).

#These authors contributed equally.

Author contributions: J.L.F. and M.Co. conceived and overviewed the project. J.L.F., T.T., and M.Co. wrote the manuscript. J.L.F., T.T., and C.S. designed experiments. J.L.F., T.T., V.R.R. and S.W. performed bioinformatical analysis. J.L.F., T.T., C.S., S.O., R.S., and B.B. performed experiments. J.L.F., T.T., and C.S. analyzed the data. W.L.B. performed electron microscopy analysis. S.K.P. provided reagents. P.F.R. and S.G. generated mouse lines. M.Ce. provided crucial insights for the study.

Disclosures: The authors declare no competing interests exist.

Fachi et al. identify LINGO4 as a key regulator of group 3 innate lymphoid cells, coordinating mitochondrial fitness and IL-22 production. LINGO4 deficiency disrupts ILC3 function and microbiota composition, altering susceptibility to enteric infections.

Keywords

LINGO4; ILC3; Gut microbiota; Mitochondrial function; *C. difficile*; *C. rodentium*; *S. Typhimurium*; IL-22

Introduction

Innate lymphoid cells (ILCs) are a family of lymphocytes that lack antigen-specific receptors yet parallel the effector functions of T helper (Th) cell subsets (Eberl et al., 2015; Klose and Artis, 2016; Vivier et al., 2018). Unlike T cells, ILCs do not undergo antigen receptor rearrangement and therefore respond rapidly to environmental cues without requiring antigen recognition, priming, or clonal expansion (Vivier et al., 2018). Among mucosal tissues, the intestine contains the highest density of ILCs, where they serve as early sentinels that integrate signals from dietary metabolites, stromal and epithelial cells, and the resident microbiota (Li et al., 2018; Wang et al., 2023; Faria et al., 2017; Klose and Artis, 2016).

Group 3 ILCs (ILC3s), defined by expression of the transcription factor ROR γ t and production of IL-22 and IL-17, are central to maintaining intestinal barrier integrity (Cella et al., 2009; Sanos et al., 2009; Eberl et al., 2004; Cupedo et al., 2009; Satoh-Takayama et al., 2008; Gury-BenAri et al., 2016). IL-22 produced by ILC3s drives epithelial proliferation, antimicrobial peptide release, and resistance to enteric pathogens, while IL-17 contributes to neutrophil recruitment and mucosal immunity (Horn and Sonnenberg, 2024; Reynders et al., 2011; Sabihi et al., 2020; Cupedo et al., 2009; Liang et al., 2006). ILC3s also shape the composition and spatial organization of the gut microbiota, and their development and effector functions are strongly influenced by microbial metabolites including aryl hydrocarbon receptor (AHR) ligands, tryptophan metabolites, and short-chain fatty acids (SCFA) (Chun et al., 2019; Fachi et al., 2025; Kiss et al., 2011; van de Pavert et al., 2014; Lehmann et al., 2020; Grizotte-Lake et al., 2018; Lee et al., 2011; Fachi et al., 2020). Through these reciprocal interactions, ILC3s function at the interface of host defense and microbial ecology, and perturbations in ILC3 activity can profoundly alter susceptibility to infection, inflammation, and dysbiosis.

ILC3 identity and function are maintained by a core transcriptional program centered on ROR γ t and AHR, which together regulate ILC3 survival, metabolic fitness, and IL-22 production (Sun et al., 2000; Eberl et al., 2004; Lee et al., 2011; Serafini et al., 2015; Sawa et al., 2010; Lo et al., 2019). LINGO4 (Leucine-rich repeat and immunoglobulin-like domain-containing protein 4) is a transmembrane protein composed of an extracellular ectodomain containing multiple leucine-rich repeats capped by cysteine-rich regions followed by an immunoglobulin-like domain, a single transmembrane segment, and a short cytoplasmic C-terminal tail. LINGO4 is encoded immediately adjacent to the *Rorc* locus and is robustly expressed in ROR γ t⁺ lineages, including ILC3s and Th17 cells, suggesting

coordinated regulation with ROR γ t and ROR γ (He et al., 1998; Sun et al., 2000). Prior studies of LINGO4 have focused largely on neuronal development (Haines and Rigby, 2008; Guillemain et al., 2020), leaving unknown whether and how LINGO4 influences mucosal immunity or the function of ROR γ t⁺ lymphocytes.

Here, we show that LINGO4 is a critical regulator of ILC3 homeostasis and effector function. Deletion of *Lingo4* results in a cell-intrinsic defect in ILC3 activation, characterized by reduced IL-22 production, impaired STAT3 phosphorylation, mitochondrial dysfunction, and increased apoptosis. In contrast, the numerical reduction of ILC3s in *Lingo4*^{-/-} mice is largely microbiota-dependent, reflecting an extrinsic defect shaped by altered microbial communities and host-microbiota interactions. Consistent with the IL-22 role in host defense, *Lingo4*-deficient mice are more susceptible to *Clostridioides difficile* (*C. difficile*) and *Citrobacter rodentium* (*C. rodentium*)-pathogens controlled by IL-22-dependent epithelial immunity, but are more resistant to *Salmonella enterica* serovar Typhimurium (*S. Typhimurium*), for which IL-22 instead promotes pathogen expansion. Together, these findings identify LINGO4 as a previously unrecognized regulator of mucosal immunity that maintains ILC3 fitness, IL-22 production, and host-microbiota homeostasis.

Results

Lingo4 deficiency impairs ILC3 numbers and function

Since *Lingo4* is encoded immediately adjacent to *Rorc*, which encodes ROR γ t, we first asked whether its expression is coordinated with ROR γ t⁺ lymphocytes. Analysis of publicly available ImmGen ATAC-seq datasets (Heng et al., 2008) revealed that immune populations with accessible chromatin at the *Rorc* locus also showed accessibility at the *Lingo4* locus (Figure S1A), consistent with shared regulatory control. Examination of ImmGen transcriptional datasets across immune subsets further revealed that *Lingo4* expression closely mirrors *Rorc* expression, with transcripts detected specifically in ROR γ t-expressing populations but not early hematopoietic progenitors (Figure S1B–S1C). This pattern suggests that *Lingo4* co-expression with *Rorc* is established at the stage of ROR γ t⁺ lineage specification. Among ROR γ t-expressing lymphocytes, *Lingo4* transcript levels were highest in ILC3 subsets, with lower expression in splenic $\gamma\delta$ T cells and thymic double-positive T cells (Figure S1C). We validated these findings by RT-qPCR using sort-purified ILC3s, CD4⁺ T cells, CD8⁺ T cells, and $\gamma\delta$ T cells from multiple tissues, confirming that ILC3s express the highest levels of *Lingo4* (Figure S1D–S1H). Sorting ROR γ t⁺ and ROR γ t⁻ cells from *Rorc*^{GFP} reporter mice further demonstrated that *Lingo4* expression is enriched in ROR γ t⁺ ILC3s, supporting its potential relevance for ILC3 biology (Figure S1I). These observations provided the rationale for generating *Lingo4*-deficient mice to directly assess its function.

Global deletion of *Lingo4* resulted in a reduction of ILC3s in the small intestinal lamina propria (siLP), whereas colonic ILC3s were unaffected (Figure 1A–1C). Among ILC3 subsets (NKp46⁺, CCR6⁺, and double-negative [DN] ILC3s), the CCR6⁺ and DN populations were proportionally reduced in siLP but not in colon (Figure 1D–1E). ROR γ t⁺ Th17 and ROR γ t⁺ pTreg cells were similarly reduced in the siLP, with no differences observed in the colon (Figure S1J–S1K). The ILC3 deficit persisted in *Rag1*^{-/-}, *Tcrb*^{-/-},

and *Tcrd*^{-/-} backgrounds (Figure S1L–S1N), indicating that the phenotype does not arise from altered T cell compartments. Because ROR γ t is essential for ILC3 lineage identity (Sun et al., 2000; Eberl et al., 2004), we asked whether LINGO4 influences its expression. ROR γ t protein levels were comparable between WT and *Lingo4*^{-/-} ILC3s (Figure 1F), demonstrating that the reduction in ILC3 numbers is not caused by impaired lineage specification. Functionally, *Lingo4*^{-/-} siLP ILC3s exhibited reduced IL-22 production, both at steady state and following IL-23 stimulation (Figure 1G). IL-17 production was only modestly affected after IL-23 stimulation, whereas IFN- γ , TNF- α , and GM-CSF were unchanged (Figure 1G and S1O). IL-22 and IL-17 were comparably reduced across all three siLP ILC3 subsets (Figure 1H and S1P). The expression of IL-23R was comparable between genotypes (Figure S1Q), indicating that reduced cytokine production is unlikely to reflect impaired IL-23 sensing or ligand binding, though downstream signaling defects cannot be excluded. Similarly to the siLP, colonic *Lingo4*^{-/-} ILC3s showed impaired IL-22 production at baseline and after IL-23 stimulation, whereas IL-17 production was reduced only following stimulation (Figure 1I).

To distinguish intrinsic from extrinsic requirements for *Lingo4*, we generated mixed bone marrow chimeras by reconstituting CD45.1 recipients with equal proportions of WT (CD45.1/CD45.2) and *Lingo4*^{-/-} (CD45.2) donor cells (Figure 1J). In this competitive environment, *Lingo4*^{-/-} ILC3s showed only a modest reduction in reconstitution, indicating that the decrease in ILC3 abundance is only minimally cell-intrinsic (Figure 1K). In sharp contrast, *Lingo4*^{-/-} ILC3s retained a pronounced defect in IL-22 production even when developing in the same host as WT ILC3s (Figure 1L), demonstrating a strong, cell-intrinsic requirement for LINGO4 in IL-22 production. Reconstitution of CD4⁺ and CD8⁺ T cells remained normal (Figure S1R). To determine whether the ILC3 defect in *Lingo4* mice depends on *Lingo4* expression in ILC3s rather than in T cells, which also express *Lingo4*, we crossed *Lingo4*^{fl/fl} mice with *Serinc2*^{Cre} (Rodrigues et al., 2025), generating *Lingo4*^{ILC3} conditional knockouts, in which *Lingo4* is deleted in ILC3s but spared in Th17 cells. *Lingo4*^{ILC3} mice partially phenocopied the global knockout, displaying reduced ILC3 numbers, predominantly within the DN subset (Figure 1M–1N), and diminished IL-22 production, whereas IL-17 production remained intact (Figure 1O). Because *Serinc2* is also expressed in the epithelial cells (Rodrigues et al., 2025), we performed RT-qPCR analysis of intestinal epithelial cells from WT mice and did not detect *Lingo4* expression (Figure S1S), suggesting that the observed phenotype in *Serinc2*^{Cre} mice is ILC3-specific. Together, these results indicate that LINGO4 exerts a dual role in ILC3 biology. The impairment in IL-22 production is predominantly cell-intrinsic and occurs independently of T cells or altered ROR γ t expression. By contrast, the reduction in ILC3 numbers reflects a modest intrinsic contribution coupled to a substantial extrinsic component.

ILC3 abundance in *Lingo4*^{-/-} mice is microbiota-dependent

ILC3 abundance is shaped by both cell-intrinsic programs and extrinsic signals from the intestinal microbiota, including food-derived metabolites such as SCFAs and AHR ligands (Gury-BenAri et al., 2016; Horn and Sonnenberg, 2024). To determine whether microbiota-dependent mechanisms contribute to the reduced ILC3 numbers in *Lingo4*^{-/-} mice, we first co-housed WT, *Lingo4*^{+/-}, and *Lingo4*^{-/-} littermates from birth. Under

these conditions, the difference in ILC3 numbers was completely normalized (Figure 2A), indicating that the numerical defect is not solely cell-intrinsic but strongly influenced by the microbial environment. In contrast, although steady-state IL-22 and IL-17 production were comparable across genotypes (Figure 2B), IL-23 stimulation revealed a selective and persistent defect in IL-22, but not IL-17, production in *Lingo4*^{-/-} ILC3s. This finding indicates that IL-22 defect is microbiota-independent and strictly cell-intrinsic. To further distinguish intrinsic from extrinsic requirements for *Lingo4*, we performed reciprocal bone marrow transfers between WT and *Lingo4*^{-/-} hosts (Figure S2A). *Lingo4*^{-/-} donor cells showed incomplete ILC3 reconstitution even in WT hosts, demonstrating a cell-intrinsic defect in the ability of *Lingo4*^{-/-} progenitors to generate or maintain ILC3s (Figure S2B). However, reconstitution was not abolished, indicating that intrinsic impairment alone does not fully account for the phenotype. Conversely, WT donor cells only partially restored ILC3 numbers in *Lingo4*^{-/-} recipients and did not reach WT→WT levels. This incomplete rescue suggests the presence of an additional extrinsic barrier in *Lingo4*^{-/-} hosts, most likely arising from microbiota perturbations, which are known to be further altered by irradiation during chimera generation. These results indicate that the ILC3 numerical defect reflects a combination of intrinsic impairment and microbiota-dependent extrinsic influences. In contrast, IL-22 production mapped entirely to donor genotype: *Lingo4*^{-/-} ILC3s failed to produce IL-22, whereas WT ILC3s produced normal IL-22 regardless of recipient genotype (Figure S2C). Together, these findings reveal a dual mechanism, in which ILC3 numbers depend on both intrinsic LINGO4 function and microbiota-derived cues, whereas IL-22 production is exclusively cell-intrinsic.

Consistent with a microbiota-dependent component to the numerical phenotype, VNAM antibiotic depletion abolished differences in ILC3 frequencies between WT and *Lingo4*^{-/-} mice (Figure 2C). Under these conditions, IL-22 levels at steady state normalized, but the IL-23-induced IL-22 defect persisted in *Lingo4*^{-/-} cells (Figure 2D), reinforcing its intrinsic nature. IL-17 responses showed intermediate sensitivity to microbiota manipulation (Figure 2D). Developmental analyses supported this interpretation: before weaning, when the microbiota is immature, ILC3 numbers were similar in WT and *Lingo4*^{-/-} mice (Figure 2E–2F). After weaning, when microbiota-derived cues intensify, ILC3 numbers declined sharply in *Lingo4*^{-/-} mice. In contrast, IL-22 production was already impaired at birth and remained defective throughout development (Figure 2G), confirming a microbiota-independent regulation. IL-17 production showed non-uniform developmental patterns (Figure S2D), consistent with partial microbiota sensitivity.

***Lingo4* deficiency induces a dysbiotic microbiota with reduced capacity to support ILC3s**

To characterize microbial alterations associated with *Lingo4* deficiency, we profiled fecal bacterial communities in cohoused and non-cohoused WT and *Lingo4*^{-/-} mice using 16S rRNA sequencing. Alpha diversity was unchanged (Figure S2E), but beta diversity revealed distinct clustering of non-cohoused WT and *Lingo4*^{-/-} microbiotas, whereas cohoused mice of both genotypes clustered together (Figure 2H and S2F). Taxonomic analysis showed that non-cohoused *Lingo4*^{-/-} mice harbored a microbiota markedly different from WT, whereas *Lingo4*^{-/-} mice cohoused with WT mice resembled WT controls (Figure 2I and S2G). Linear Discriminant Analysis Effect Size (LEfSe) confirmed widespread

taxonomic differences between genotypes under non-cohoused conditions (Figure S2H–S2I). Cohousing drove extensive restructuring of the *Lingo4*^{-/-} microbiota (Figure S2J), but WT microbiota remained stable (Figure S2K), revealing asymmetric microbial transfer from WT → *Lingo4*^{-/-} mice. Key differences in non-cohoused *Lingo4*^{-/-} mice included loss of SCFA-producing families (*Muribaculaceae*, *Firmicutes*) and expansion of dysbiosis-associated taxa (*Tannerellaceae*, *Helicobacteraceae*, *Rhodospirillales*) (Figure S2H–S2K).

PICRUSt2 functional inference showed that WT microbiota was enriched for SCFA-related metabolic pathways, while *Lingo4*^{-/-} microbiota favored nitrogenous waste metabolism and menaquinone/quinone biosynthesis, features characteristic of inflamed or dysbiotic ecosystems (Figure S3A). Because the microbiota of *Lingo4*^{-/-} mice exhibited major shifts in metabolic potential, particularly in pathways linked to fermentation of complex carbohydrates and SCFA production, and because such diet-derived metabolites are known regulators of ILC3 homeostasis (Chun et al., 2019; Fachi et al., 2020), we asked whether dietary inputs would differentially modulate ILC3 abundance in WT and *Lingo4*^{-/-} mice. Dietary manipulation revealed that ILC3 abundance is sensitive to microbiota-driven metabolic cues in both genotypes, but with distinct magnitude effects. A high-fat diet reduced ILC3 numbers in WT mice and further exacerbated the deficit in *Lingo4*^{-/-} mice relative to mice maintained on conventional chow, consistent with diet-induced dysbiosis (Figure S3B). Conversely, a high-fiber diet significantly increased ILC3 numbers in WT mice, whereas only a modest trend was observed in *Lingo4*^{-/-} mice (Figure S3C), suggesting that fiber supplementation cannot fully overcome the underlying dysbiotic state in the *Lingo4*^{-/-} mice. Under low-fiber conditions, both WT and *Lingo4*^{-/-} mice exhibited similarly reduced ILC3 numbers, consistent with impaired microbial metabolic support in both groups. Together, these findings indicate that *Lingo4* deficiency creates a microbial and metabolic environment less capable of sustaining ILC3 homeostasis, and that diet interacts with this altered microbial landscape in a genotype-dependent manner, providing functional support for the conclusion that microbial metabolic capacity contributes to the ILC3 phenotype.

WT microbiota restores ILC3 numbers in *Lingo4*^{-/-} mice but fails to rescue intrinsic IL-22 defects

Because both the composition and metabolic potential of the *Lingo4*^{-/-} microbiota were altered, and because ILC3 numbers showed microbiota dependence, we next asked whether the *Lingo4*^{-/-} microbial community is sufficient to transfer the ILC3 phenotype and whether restoring a WT microbiota can rescue it. To directly test this, we performed fecal microbiota transplantation (FMT) between WT and *Lingo4*^{-/-} mice (Figure 3A). Recipients were pretreated with a Vancomycin, Neomycin, Ampicillin, and Metronidazole (VNAM) antibiotic cocktail for four weeks to deplete endogenous microbiota and were analyzed 21 days after FMT to allow microbial reconstitution (Figure 3B). Transfer of WT microbiota normalized ILC3 numbers in both WT and *Lingo4*^{-/-} recipients (Figure 3C), demonstrating that a WT microbial community is sufficient to restore ILC3 abundance even in a *Lingo4* deficient host. In contrast, transfer of *Lingo4*^{-/-} microbiota reduced ILC3 numbers in both genotypes (Figure 3C), establishing that the dysbiotic *Lingo4*^{-/-} microbiota is sufficient to drive the ILC3 numerical defect. Cytokine production displayed distinct dependencies on

genotype versus baseline microbiota composition. Although exposure to WT microbiota modestly increased IL-22 and IL-17 production by *Lingo4*^{-/-} ILC3s (WT→KO) compared to *Lingo4*^{-/-} mice that received *Lingo4*^{-/-} microbiota (KO→KO) (Figure 3D–3E), genotype remained the dominant determinant of cytokine output. *Lingo4*^{-/-} mice maintained lower IL-22 and IL-17 levels than WT mice even after receiving WT microbiota, as shown by comparing WT→KO with WT→WT. Similarly, IL-22 production by WT ILC3s was not impaired by the *Lingo4*^{-/-} microbiota, as shown by comparing KO→WT and KO→KO, or WT→WT and KO→WT (Figure 3D). Although IL-17 production was reduced in WT ILC3s following transfer of *Lingo4*^{-/-} microbiota (KO→WT vs. WT→WT), WT ILC3s still produced higher levels of IL-17 than *Lingo4*^{-/-} ILC3s in the same microbial context (KO→WT vs. KO→KO). Together, these findings indicate that the IL-22 defect is primarily cell-intrinsic and can be minimally rescued by restoring a normal microbial environment, and the IL-17 defect is partial and context-dependent rather than absolute.

Microbiota profiling revealed genotype-dependent colonization dynamics after FMT. WT recipients rapidly acquired the *Lingo4*^{-/-} microbiota by day 7, but this profile was not maintained by day 21, suggesting that the WT gut environment gradually outcompetes dysbiotic taxa (Figure 3F and S3D). In contrast, *Lingo4*^{-/-} recipients failed to engraft WT microbiota at day 7 but successfully acquired it by day 21, indicating delayed colonization likely linked to reduced IL-22-dependent barrier function. These dynamics were reflected at the family and genus levels (Figure 3G and S3E). Across all time points, *Lingo4*^{-/-} mice exhibited persistent expansion of *Proteobacteria*, a phylum associated with dysbiosis and barrier dysfunction, and reduced *Firmicutes*, trends supported by MaAsLin2 analysis (Figure S3F–S3H). LEfSe further showed that *Lingo4*^{-/-} recipients acquired a broader and more dysbiosis-associated set of taxa than WT recipients: at day 7, *Lingo4*^{-/-} mice were enriched for *Bacteroidaceae*, *Akkermansia*, and *Verrucomicrobiae*, and by day 21 they expanded *Alphaproteobacteria* and *Rhodospirillales*, whereas WT recipients showed enrichment of *Lachnospiraceae* and *Bacteroidales* early, and *Bacteroides* and *Gammaproteobacteria* later, patterns more consistent with microbiota stabilization than persistent dysbiosis (Figure 3H). Together, these results demonstrate that the *Lingo4*^{-/-} microbiota is necessary and sufficient to reduce ILC3 abundance, explaining the extrinsic component of the ILC3 numerical phenotype, whereas IL-22 production remains mainly cell-intrinsic and unaffected by microbiota normalization, and that *Lingo4* deficiency alters the host environment in ways that delay microbial engraftment and favor expansion of dysbiosis-associated taxa following FMT.

***Lingo4* deficiency impairs microbiota-driven protection against *C. difficile* and *C. rodentium* infections**

ILC3-derived IL-22 is a key mediator of epithelial defense and protection against intestinal pathogens (Jarade et al., 2022; Sonnenberg et al., 2011; Cella et al., 2009; Sanos et al., 2009; Satoh-Takayama et al., 2008). Because *Lingo4*^{-/-} mice exhibit a pronounced, cell-intrinsic defect in IL-22 production and a microbiota-dependent reduction in ILC3 numbers, we next examined whether these impairments increase susceptibility to enteric infection. As an initial model of microbiota-dependent infection, we used *C. difficile*, an anaerobic, spore-forming pathogen that requires disruption of the gut microbiota for efficient colonization and

causes toxin-mediated colitis (Abt et al., 2016). Following standard antibiotic conditioning (Chen et al., 2008), WT and *Lingo4*^{-/-} mice developed comparable disease during the early phase of infection; however, *Lingo4*^{-/-} mice exhibited significantly increased disease severity at later stages, as shown by greater weight loss and clinical scores on days 4 and 5 p.i. (Figure S4A–S4C). In contrast, when infection was performed without antibiotic pretreatment, thereby preserving microbiota-mediated colonization resistance, WT mice displayed minimal disease, whereas *Lingo4*^{-/-} mice were highly susceptible and developed marked pathology (Figure S4D–S4F). These findings indicate that *Lingo4* deficiency compromises microbiota-driven colonization resistance to *C. difficile*.

To assess whether LINGO4 also regulates susceptibility to microbiota-independent infection, we challenged both cohoused and separately housed WT and *Lingo4*^{-/-} mice with *C. rodentium*, a mucosal pathogen and the murine equivalent of human enterohemorrhagic *E. coli* (Collins et al., 2014). Non-cohoused *Lingo4*^{-/-} mice showed the greatest susceptibility, with more severe body weight loss, elevated early fecal bacterial burdens, and delayed pathogen clearance relative to WT mice (Figure 4A–4B). These mice also exhibited classic signs of mucosal injury, including shortened colon length (Figure 4C), increased fecal Lipocalin-2 (Figure 4D), and enhanced gut permeability measured by serum FITC-dextran (Figure 4E). Histopathology confirmed more extensive tissue damage in both small intestine and colon (Figure 4F), accompanied by increased colonic myeloid infiltration (Figure 4G). In parallel, non-cohoused *Lingo4*^{-/-} mice showed marked reductions in ILC3 numbers and diminished production of IL-22, IL-17, and IFN- γ in small intestine (Figure 4H–I) as well as in colon (Figure 4J–K), consistent with a failure to mount effective mucosal immune responses. Notably, co-housing *Lingo4*^{-/-} with WT mice partially mitigated disease severity, reducing weight loss and bacterial burden relative to non-cohoused *Lingo4*^{-/-} mice (Figure 4A–4B), consistent with microbiota-mediated rescue of ILC3 abundance.

To directly test whether IL-22 deficiency is responsible for the increased susceptibility of *Lingo4*^{-/-} mice, we manipulated IL-22 signaling during *C. rodentium* infection (Figure 4L). IL-22 blockade in WT mice eliminated their natural resistance, producing a disease course that phenocopied non-cohoused *Lingo4*^{-/-} mice and further increasing susceptibility in *Lingo4*^{-/-} mice (Figure 4M–N). Conversely, treatment with recombinant IL-22 fully restored resistance to *C. rodentium* in *Lingo4*^{-/-} mice to levels comparable to WT controls. These findings demonstrate that impaired IL-22-dependent mucosal immunity is a major driver of the heightened susceptibility of *Lingo4*^{-/-} mice, and that restoring IL-22 is sufficient to reverse this defect.

Finally, because *Lingo4* transcript is also expressed in select T cell subsets (Figure S1C–S1I), we tested whether aberrant T cell function contributes to the infection phenotype, given prior evidence implicating T cells in the regulation of host responses (Zindl et al., 2024). *Lingo4*^{-/-} mice crossed to *Rag1*^{-/-}, *Tcrb*^{-/-}, or *Tcrd*^{-/-} backgrounds remained highly susceptible to *C. rodentium* infection compared with their *Lingo4*^{+/+} counterparts (Figure S4G–S4N), demonstrating that the increased susceptibility of *Lingo4*^{-/-} mice is independent of $\alpha\beta$ and $\gamma\delta$ T cells. Together, these results show that *Lingo4* deficiency compromises both microbiota-mediated protection and IL-22-driven mucosal immunity, leading to heightened

vulnerability to intestinal pathogens; co-housing with WT mice and IL-22 supplementation each partially correct distinct components of this defect.

***Lingo4* deficiency protects against *S. Typhimurium* by limiting IL-22**

Because IL-22 can play a detrimental role during *S. Typhimurium* infection by inducing antimicrobial programs that suppress protective commensal competitors but spare *S. Typhimurium*, thereby promoting pathogen expansion (Behnsen et al., 2014; Xiong et al., 2022), we reasoned that the intrinsic IL-22 defect in *Lingo4*^{-/-} mice might confer relative protection to this pathogen. Consistent with this hypothesis, non-cohoused *Lingo4*^{-/-} mice were significantly more resistant to *S. Typhimurium* challenge than WT controls, exhibiting improved survival, reduced body weight loss, lower fecal bacterial burdens (Figure 5A–5C), and decreased bacterial dissemination to mesenteric lymph nodes and liver (Figure S5A–S5D). *Lingo4*^{-/-} mice also showed reduced colon shortening (Figure S5E), lower histopathological scores in both small intestine and colon (Figure 5D–5E), increased goblet cell numbers (Figure 5F), and reduced neutrophil infiltration (Figure 5G), indicating enhanced barrier integrity and attenuated inflammation. Importantly, streptomycin pretreatment, which is commonly used to facilitate infection in WT mice by inducing dysbiosis (Walker et al., 2023), abolished the enhanced resistance of *Lingo4*^{-/-} mice, indicating that their protection depends on an intact commensal microbiota and is lost when the microbiota is disrupted.

To identify the mechanism underlying this enhanced resistance, we assessed ILC3 responses and found that ILC3 frequencies and IL-22 production were markedly reduced in *Lingo4*^{-/-} mice on day 5 p.i. (Figure 5H–5I), consistent with diminished IL-22-driven suppression of commensals. To directly test the role of IL-22, we manipulated IL-22 signaling during infection. Neutralization of IL-22 increased survival of WT mice, rendering them phenotypically similar to *Lingo4*^{-/-} mice, whereas administration of recombinant IL-22 eliminated protection in *Lingo4*^{-/-} mice and further worsened outcomes in WT mice (Figure 5J–5L). These experiments demonstrate that reduced IL-22 production is the key driver of the enhanced resistance of *Lingo4*^{-/-} mice to *S. Typhimurium*, by limiting pathogen-favoring suppression of the microbiota.

Because *Lingo4* transcript is expressed in select T cell subsets and conventional CD4⁺ T cells contribute to late-stage pathogen control (Pedicord et al., 2016; van der Velden et al., 2005; Clay et al., 2020), we examined whether T cells participate in this phenotype. Although CD4⁺ T cell numbers were modestly reduced in *Lingo4*^{-/-} mice at day 5 p.i. (Figure S5F), the protective phenotype persisted when WT and *Lingo4*^{-/-} mice were compared on a *Rag1*^{-/-} background but was lost following streptomycin pretreatment (Figure S5G–S5H). These results indicate that the enhanced resistance of *Lingo4*^{-/-} mice is driven primarily by reduced ILC3 abundance and diminished IL-22 production, rather than by alterations in conventional T cell compartments.

LINGO4 controls ILC3 activation through mitochondrial regulation

To investigate the mechanistic basis of LINGO4 function, we generated a LINGO4-overexpressing 293T cell line in which an N-terminal FLAG tag and a C-terminal 6xHis tag

were fused to LINGO4 (Figure 6A). Flow cytometry and anti-FLAG immunofluorescence revealed that LINGO4 is expressed predominantly intracellularly, with lower surface expression (Figure 6A–6B). Immunoprecipitation of LINGO4 with anti-FLAG antibody followed by mass spectrometry identified proteins enriched in LINGO4-expressing cells but not control 293T cells (Table S1), and pathway analysis of these interactors revealed strong associations with mitochondrial and endoplasmic reticulum (ER) processes, including mitochondrial membrane transport, calcium trafficking, and protein folding (Figure 6C). Notably, bulk RNA sequencing of sort-purified ILC3s from *Lingo4*^{-/-} and WT mice revealed a similar enrichment of pathways linked to mitochondrial function and ER protein processing (Figure 6D), suggesting that LINGO4 regulates fundamental metabolic and organelle-associated processes in ILC3s.

Given that mitochondrial metabolism is essential for ILC3 activation, proliferation, and cytokine production, including IL-22 and IL-17 (Di Luccia et al., 2019; Yu et al., 2022), we examined mitochondrial structure and function in *Lingo4*-deficient ILC3s. Electron microscopy of sort purified siLP ILC3s showed that *Lingo4*^{-/-} ILC3s have reduced mitochondrial matrix density, indicative of structural abnormalities (Figure 6E). MitoTracker Green staining of WT and *Lingo4*^{-/-} ILC3s revealed no difference in mitochondrial mass at steady state or following IL-23 stimulation, and baseline mitochondrial membrane potential shown by MitoTracker Red staining was comparable between genotypes (Figure 6F). However, upon IL-23 stimulation, WT ILC3s increased their mitochondrial membrane potential, whereas *Lingo4*^{-/-} ILC3s failed to undergo this metabolic activation (Figure 6F), demonstrating an impaired ability to engage mitochondrial respiration during activation.

We next assessed mitochondrial reactive oxygen species (mROS) by mitoSOX staining. *Lingo4*^{-/-} ILC3s produced significantly more mROS than WT ILC3s (Figure 6G), consistent with metabolic stress. Because excessive mROS promotes lipid peroxidation, we quantified oxidized lipids using BODIPY 581/591 C11. *Lingo4*^{-/-} ILC3s displayed elevated lipid accumulation and lipid peroxidation (Figure 6H), indicating impaired cellular metabolism and oxidative damage to mitochondrial membranes. STAT3 activation integrates cytokine signaling with mitochondrial metabolic programming in ILC3s (Lehmann et al., 2020; Guo et al., 2014; Teufel et al., 2021). Although *Lingo4* deficiency did not impair ROR γ t expression (Figure 1F), *Lingo4*^{-/-} ILC3s exhibited reduced phosphorylation of STAT3 following IL-23 stimulation (Figure 6I). These data suggest that defective STAT3 activation, together with mitochondrial dysfunction, underlies the impaired IL-22 production observed in *Lingo4*^{-/-} ILC3s. Because lipid peroxidation and mitochondrial damage can trigger apoptosis, we assessed cell survival. Annexin V staining revealed that *Lingo4*^{-/-} ILC3s contained more early apoptotic cells and fewer viable cells than WT ILC3s (Figure 6J), whereas Ki67 staining showed normal proliferative capacity (Figure 6K). These results suggest that reduced ILC3 abundance in *Lingo4*^{-/-} mice arises primarily from increased susceptibility to apoptosis rather than impaired proliferation.

Finally, to confirm that the impaired mitochondrial phenotype is intrinsic to ILC3s, we analyzed *Lingo4*^{ΔILC3} mice. Compared with *Lingo4*^{fl/fl} controls, ILC3s from *Lingo4*^{ΔILC3} mice exhibited significantly increased mitochondrial ROS (Figure 7A), elevated lipid peroxidation (Figure 7B), reduced STAT3 phosphorylation (Figure 7C), and enhanced

apoptosis (Figure 7D). Consistent with these cellular defects, *Lingo4^{ILC3}* mice were more susceptible to *C. rodentium* infection, as reflected by greater body weight loss (Figure 7E) and higher fecal bacterial burden (Figure 7F). Moreover, *Lingo4^{ILC3}* mice showed a marked reduction in colonic ILC3 numbers and diminished production of IL-22 and IL-17, but not IFN- γ , TNF- α , or GM-CSF (Figure 7G–I), consistent with the phenotype observed in *Lingo4^{-/-}* mice (Figure 4).

Together, these findings indicate that LINGO4 sustains ILC3 survival and effector function by preserving mitochondrial fitness, limiting mROS, maintaining STAT3 activation, and preventing apoptosis. Loss of LINGO4 impairs IL-22 production intrinsically, compromising epithelial barrier integrity and promoting dysbiosis. Consistent with prior studies showing that reduced IL-22 drives transmissible dysbiosis (Zenewicz et al., 2013), whereas enhanced IL-22 signaling promotes protective microbial communities (Fachi et al., 2024), the microbiota alterations in *Lingo4^{-/-}* mice reflect diminished IL-22 output. The resulting dysbiotic environment further restricts ILC3 maintenance, establishing a dual mechanism: a primary cell-intrinsic metabolic defect and a secondary microbiota-dependent amplification of ILC3 loss.

Discussion

This study identifies LINGO4 as a previously unrecognized, dual regulator of ILC3 biology that couples cell-intrinsic effector programs to microbiota-dependent homeostasis. Members of the LINGO family (LINGO1–4) share conserved structural features, including leucine-rich repeats and immunoglobulin-like domains, and have been primarily studied in the context of neuronal signaling (Guillemain et al., 2020). LINGO1 has been extensively characterized in the nervous system, where it functions as a regulatory subunit of large-conductance Ca^{2+} -activated potassium channels and has been implicated in tremor and neurodegenerative disorders (Dudem et al., 2020; Mi et al., 2007; Inoue et al., 2007). LINGO2 and LINGO3 have emerged as modulators of intestinal epithelial biology, acting as components of receptor complexes for trefoil factors that regulate EGFR signaling, mucosal wound healing, stem cell maintenance, and host defense during colitis and helminth infection (Belle et al., 2019; Zullo et al., 2021). Despite these advances, LINGO4 has remained largely unexplored, with prior studies primarily linking its expression to embryonic neuronal development and no established role in immune regulation (Haines and Rigby, 2008; Guillemain et al., 2020). Here, we demonstrate that LINGO4 is highly expressed in $\text{ROR}\gamma\text{T}^+$ ILC3s and is intrinsically required for their metabolic fitness, STAT3 activation, IL-22 production, and survival. By extending the functional repertoire of the LINGO family beyond neuronal and epithelial compartments, these findings uncover LINGO4 as a regulator that fine-tunes ILC3 function and IL-22-dependent intestinal barrier immunity.

Our work advances the ILC3 field in several important ways. First, it uncouples ILC3 numbers from effector function by demonstrating that LINGO4 plays a strongly cell-intrinsic role in regulating IL-22 production, while contributing only modestly and indirectly to ILC3 numbers. ILC3s serve as key sentinels of the intestinal barrier, producing IL-22 to promote epithelial defense, shape commensal microbial communities, and restrict pathogen

expansion (Horn and Sonnenberg, 2024), yet the mechanisms that separately govern their functional output versus population size have remained poorly defined. Using mixed bone marrow chimeras and ILC3-specific deletion, we show that the defect in IL-22 production is strictly intrinsic to *Lingo4*-deficient ILC3s. In contrast, co-housing, antibiotic treatment, developmental timing, dietary interventions, and fecal microbiota transplantation collectively demonstrate that reduced ILC3 abundance arises predominantly from extrinsic, microbiota-dependent cues. Consistent with prior work, microbial composition, microbially derived metabolites, and microbial regulation of IL-23, are well positioned to influence ILC3 survival, activation, and tissue adaptation (Buonocore et al., 2010; Hou et al., 2022; Kabil et al., 2025; Fachi et al., 2020; Chun et al., 2019).

Second, we define a metabolic mechanism downstream of LINGO4 in the context of emerging evidence that mitochondrial fitness is central to ILC3 effector programs. *Lingo4*-deficient ILC3s display abnormal mitochondrial ultrastructure, fail to increase mitochondrial membrane potential upon activation, accumulate mROS and lipid peroxidation products, show reduced STAT3 phosphorylation, and undergo increased apoptosis despite preserved proliferation. Consistent with prior work demonstrating that ILC3s integrate glycolysis with mitochondrial respiration and mROS generation to sustain HIF1 α activity, ROR γ t expression, and IL-22 production (Di Luccia et al., 2019; Pral et al., 2021; Wu et al., 2022; Yu et al., 2022; Fonseca-Pereira et al., 2025), our data indicate that LINGO4 is required to couple mitochondrial dynamics to cytokine output. Together, this places LINGO4 upstream of a mitochondrial-STAT3 axis that is essential for ILC3 activation and IL-22 output, aligning with current models in which metabolic sensors and mitochondrial signaling pathways calibrate tissue-resident ILC3 survival, homeostasis, and barrier-protective function.

A third advance of this study is the identification of LINGO4 as a context-dependent regulator of IL-22 production and ILC3 homeostasis with opposing effects across enteric infections. In *C. difficile* and *C. rodentium* models, where IL-22-mediated epithelial repair and antimicrobial peptide production are protective (Abt et al., 2015; Fachi et al., 2020; Zheng et al., 2008; Zhu et al., 2022), *Lingo4* deficiency compromises microbiota-mediated colonization resistance and IL-22-dependent barrier immunity, resulting in exacerbated disease. In contrast, during *S. Typhimurium* infection, where IL-22 can promote pathogen expansion by suppressing protective commensals (Xiong et al., 2022; Behnsen et al., 2014), the intrinsic IL-22 defect in *Lingo4*^{-/-} ILC3s confers a survival advantage by limiting pathogen-favoring dysbiosis. These findings highlight that IL-22 is not uniformly beneficial and position LINGO4 as a molecular rheostat that tunes IL-22 output and ILC3 metabolic fitness to shape host-pathogen interactions. Notably, LINGO4 is located near the human *RORC* locus and is expressed in human ROR γ t⁺ lymphocyte subsets, suggesting that variation in LINGO4 expression or function may influence susceptibility to ILC3-driven diseases such as inflammatory bowel disease, *C. difficile* colitis, or invasive *Salmonella* spp. infection. Together, these data raise the possibility that targeting LINGO4 or its downstream pathways could enable selective modulation of IL-22 responses, enhancing epithelial protection and microbiota stability in some settings while restraining IL-22-driven pathogen expansion or inflammation in others.

The precise molecular interactors that link LINGO4 to mitochondrial and ER homeostasis remain undefined. Given that mass spectrometry identified protein interactors involved also in ER compartment and protein processing, LINGO4 may function at the interface of mitochondrial metabolism and vesicular trafficking, potentially influencing autophagy-lysosomal pathways. This possibility is supported by parallels with another leucine-rich repeat protein, LRRK2, which connects vesicle dynamics to mitochondrial integrity (Wang et al., 2012; Weindel et al., 2020). It also remains to be determined whether analogous LINGO4-dependent mechanisms operate in human ILC3s or Th17 cells in vivo. In parallel, although our microbiome analyses identify major taxonomic and functional shifts in *Lingo4*^{-/-} mice, the specific microbial species and metabolites that support or impair ILC3 homeostasis have yet to be defined. Future studies dissecting LINGO4 signaling complexes, examining human tissues, and functionally testing candidate microbial metabolites will be important for extending these findings to broader principles of ROR γ ⁺ lymphocyte biology and for informing potential therapeutic strategies in mucosal disease.

Material and Methods

Mice

All the protocols and procedures involving animals were approved by Institutional Animal Care and Use Committee (IACUC) at Washington University in St. Louis. All mice were bred and maintained at specific-pathogen free facility at Washington University in St. Louis, USA. C57BL/6J, B6.SJL-*Ptprca*^a *Pepc*^b/BoyJ (CD45.1), C57BL/6J-*Rag1*^{em10Lutz}/J (*Rag1*^{-/-}), B6.129P2-*Tcrb*^{tm1Mom}/J (*Tcrb*^{-/-}) and B6.129P2-*Tcrd*^{tm1Mom}/J (*Tcrd*^{-/-}) mice were purchased from Jackson Laboratory. *Serinc2*^{iCre} mice were previously generated by our group (Rodrigues et al., 2025). *Lingo4*^{-/-} and *Lingo4*^{fl/fl} mice were generated at the Washington University School of Medicine in St. Louis. The *Lingo4* allele deletion was generated by CRISPR/Cas9 endonuclease-mediated genome editing. Two guide RNAs (gRNAs) were chosen to include the portion of exon 2 encoding the signal peptide of *Lingo4*: MS872.Lingo4.sp12 (TACTGATGCTCCCTCCAGGCNGG) and MS872.Lingo4.sp6 GTGACTGCACCTCCCAGACCNGG). gRNAs and a plasmid encoding Cas9 were introduced into C57BL/6J embryos, which were transferred into pseudo-pregnant females. Several founders were identified by sequencing of the targeted region, and we chose one with a 37 bp insertion created by a 7 bp deletion along with a 44 bp insertion derived from the gRNA scaffold portion of the SpCas9 plasmid. This deletion/insertion disrupted translation/expression of *Lingo4*. For the generation of *Lingo4*^{fl/fl} mice, CRISPR-Cas9 ribonucleoproteins comprising Cas9 protein and gRNAs targeting two regions flanking exon2 were introduced into C57BL/6J zygotes together with LoxP sites complementary to the targeted regions at 0.5 days post-fertilization by electroporation. The edited embryos were then transferred into D0.5 pseudo-pregnant C57BL/6J recipient females. Confirmed founders were bred to C57BL/6J mice, and the line was maintained as *Lingo4*^{fl/fl} homozygous mice. *Serinc2*^{iCre} were backcrossed to *Lingo4*^{fl/fl} mice (*Lingo4*^{ΔILC3}). *Tcrb*^{-/-}, *Tcrd*^{-/-} and *Rag1*^{-/-} mice were backcrossed to *Lingo4*^{-/-} mice. Experiments were conducted using sex-matched mice aged 7-14 weeks that were either non-cohoused or cohoused from birth. Up to 5 mice were housed in filtered cages with corn cob bedding,

provided with standard chow diet and drinking water *ad libitum*, and subjected to 12-hour light:12-hour dark cycles. Cages were cleaned weekly in a laminar airflow cabinet.

Generation of 293T cell line expressing *Lingo4*

Lingo4, flanked by FLAG-tag at N-terminus and 6xHis tag at C-terminus, was cloned into pLVX-EF1a-IRES-mCherry vector (Clontech Laboratories, Inc., No. 631987) by Gibson Assembly Cloning Kit (NEB) and confirmed by sequencing. Lentiviral packaging was performed in the 293T packaging cell line (ATCC, CRL-3216) with Lipofectamine 2000 (Thermo Fisher Scientific) per manufacturer's protocol. Cells were co-transfected with psPAX2 packaging plasmid (Addgene No. 12260), pCMV-VSV-G envelope plasmid (Addgene No. 8454), and pLVX-EF1a-IRES-mCherry expressing FLAG-*Lingo4*-6xHis. Viral supernatants were harvested 48h post-transfection and passed through 0.45 μ m filters. Transduction of 293T cells was conducted in the 12-well plate with 1 mL of filtered viral supernatant supplemented with polybrene (8 μ g/mL), and centrifugation at 900g for 1.5 hours at RT. The medium was changed next day, and cells were cultured for an additional five days. Stably transduced cells were sorted based on mCherry fluorescence using a BD FACS Aria II cell sorter.

Isolation of intraepithelial lymphocytes (IEL) and lamina propria (LP) cells

Small intestine or colon was harvested from mice, cleaned of Payer's patches and/or luminal content and opened lengthwise. Intraepithelial lymphocytes were isolated by incubating the tissue in Hank's balanced salt solution (HBSS) with HEPES, 10% bovine calf serum (BCS) and 5 mM EDTA for 20 minutes on the rotator, followed by vigorous vortexing, and another round of incubation in HBSS, and vortexing. DL-Dithiothreitol (MilliporeSigma) at final concentration of 5 mM was added to supernatants for additional 20 min incubation. For LP cells extraction, the tissue was further digested in 10% RPMI medium containing 1mg/mL collagenase IV (MilliporeSigma) for 40 min with vigorous shaking at 37°C. Both, IEL and LP leukocytes were purified by density gradient centrifugation using a 40% and 70% Percoll (Cytiva) gradient.

Flow cytometry

Single cell suspensions were incubated in the Fc block (2.4G2) and immunostained with the following anti-mouse antibodies: CD45 (30-F11), CD11b (M1/70), CD11c (N418), F4/80 (BM8), Ly6C (HK1.4), Ly6G, (1A8), I-A/I-E (M5/114.15.2), CD170 (Siglec-F; S17007L), NKp46 (CD335; 29A1.4), IL-17 (TC11-18H10.1), IFN- γ (XMG1.2), TNF- α (MP6-XT22), GM-CSF (MP1-22E9), CD45.1(A20), CD45.2 (104), NK1.1 (PK136), Thy1.2 (CD90.2; 30-H12), CD8 (53-6.7), CD4 (GK1.5), TCR γ/δ (GL3), CD3e (145-2C11), CD19 (6D5), Foxp3 (MF-14), KLRG1 (2F1/KLRG1) (all Biolegend), CCR6 (CD196; 140706), GATA3 (L50-823), T-bet (04-46), Ki67 (16A8) (all BD Biosciences); IL-22 (1H8PWSR) and RORgt (AFKJS-9) (both eBio/ThermoFisher); anti-FLAG (#200-310-B13, Rockland); and Alexa-fluor-647 goat anti-mouse IgG (H+L) (A-21236, Invitrogen). Dead cells were excluded using the Zombie Aqua™ Fixable Viability Kit (BioLegend). Cell counting was performed using counting beads (eBioscience). For intracellular staining, cells were fixed and permeabilized using the Cytofix/Cytoperm™ Fixation/Permeabilization Kit (BD Biosciences), and for transcription factor staining Foxp3/Transcription Factor Staining

Buffer Set (BD Biosciences). For cytokine analysis, cells were stimulated with 10 ng/mL IL-23 (Proteintech) for 3h with addition of GolgiPlug (BD Biosciences). Mitochondria analysis was performed by staining of cells with MitoTracker™ Green FM (#M7514), MitoTracker™ Red FM (#M22425), mitoSOX™ Red mitochondrial superoxide indicator (#M36008) or BODIPY™ 581/591 C11 (#D3861) for 30 min at 37°C following surface cell staining. pSTAT3-staining was performed with ant-pSTAT3 (pY795; BD Biosciences) antibody in methanol-fixed cells. ILC3 apoptosis was assessed with the BD Pharmingen™ PE Annexin V Apoptosis Detection Kit I (BD Biosciences). Flow cytometry was conducted on FACS-Canto or FACS-Symphony flow cytometers using BD FACS-Diva Software (BD Biosciences) for sample acquiring and FlowJo v.9.5.2 (Tree Star) for data analysis.

Bone marrow chimera experiments

Recipient mice were irradiated with a single dose of 11 Gy. Reciprocal chimeras were intravenously injected with 5×10^6 of donor cells. Competitive bone marrow chimeras were intravenously injected with 1:1 mixture of 5×10^6 of each donor cells. After 8 weeks, the efficiency of hematopoietic reconstitution was assessed by quantifying the proportion of donor cells in the spleen.

Depletion of microbiota by VNAM treatment

For microbiota depletion, mice were provided with a mixture of broad-spectrum antibiotics, VNAM: 0.5 mg/mL vancomycin, 1 mg/mL neomycin, 1 mg/mL amoxicillin, and 1 mg/mL metronidazole (all Sigma-Aldrich) in drinking water *ad libitum* for indicated period. VNAM containing water was replaced weekly for the treatments longer than one week.

Fecal microbiota transfer (FMT)

The FMT solution was prepared by resuspending two fecal pellets in cold PBS in 1 mL tubes, followed by vigorous vortexing. The resulting slurry was then filtered through a 100 µm-pore diameter nylon cell strainer (BD Falcon). Mice were given the VNAM antibiotic cocktail *ad libitum* in their drinking water for 4 weeks. Starting one day after the end of VNAM treatment, mice were administered 200 µL of the FMT suspension by oral gavage for two consecutive days.

High-fat and fiber diet regimens

Mice were fed either a standard chow diet (SD; Purina PicoLab Rodent Diet 20), a high-fat diet (RD Western Diet, D12079B), low fiber diet containing 5% cellulose (D10012M), or a high fiber diet containing 5% cellulose plus 10% soluble inulin (D19071901) for 14 days prior to ILC3 analysis. All diets were purchased from Research Diets, Inc.

***Citrobacter rodentium* infection**

Kanamycin-resistant *C. rodentium* strain DBS120 was grown overnight at 37°C in Luria-Bertani (LB) broth supplemented with kanamycin (50 µg/mL) with vigorous shaking. The next day, 200 µL of the overnight culture was inoculated into 100 mL of fresh sterile LB broth containing Kan and incubated for 3-4 hours at 37°C with vigorous shaking until reaching mid-log phase. The culture was adjusted to 1×10^{10} colony-forming units (CFU)

per mL. Mice were orally gavaged with 200 μ L containing 2×10^9 CFU. Body weight was monitored every two days. Fecal samples were collected at defined time points post-infection, weighed, and resuspended in 1 mL of sterile PBS. The samples were vortexed vigorously and allowed to settle for 10 minutes. Supernatants were serially diluted up to 10^{-6} and plated on LB agar plates containing Kan, followed by overnight incubation at 37°C.

***Clostridioides difficile* infection**

The *C. difficile* VPI 10463 strain was cultured on BHI blood agar at 37°C under anaerobic conditions using BD GasPak™ EZ Anaerobe Container System Sachets with Indicator. Mice were pre-treated with an antibiotic cocktail (0.4 mg/mL kanamycin, 0.035 mg/mL gentamicin, 0.035 mg/mL colistin, 0.215 mg/mL metronidazole and 0.045 mg/mL vancomycin; all from Sigma Aldrich) provided ad libitum in drinking water for 4 days. One day after completing antibiotic treatment, mice received an intraperitoneal (i.p.) injection of clindamycin (10 mg/kg; Sigma Aldrich), and the following day were infected via oral gavage with 10^8 CFU of *C. difficile* spores. Mice were weighed daily and monitored for disease severity by a blinded evaluator using a scoring system ranging from 0 (normal) to 15 (dead), based on activity, posture, coat condition, diarrhea, and ocular/nasal discharge, with each category scored from 0 to 3.

***Salmonella enterica* serovar Typhimurium infection**

S. Typhimurium strain SL1344 engineered to express kanamycin resistance was grown overnight at 37°C in LB broth supplemented with kanamycin (50 μ g/mL) with vigorous shaking. The following day, 200 μ L of the overnight culture was transferred into 100 mL of fresh sterile LB with Kan and grown for additional 3-4 hours at 37°C with vigorous shaking until the culture reached mid-log phase. Mice were then orally administered with 100 μ L of bacterial suspension containing 1×10^7 CFU. Twenty-four hours prior to infection, mice were pre-treated with 20 mg of streptomycin sulfate solution in sterile water by oral gavage. Water and food were withdrawn 4h before gavages; water was resumed immediately and food was provided 2 h post-infection. Body weight was assessed daily throughout the experiment. To determine fecal *S. Typhimurium* burden, stool pellets were homogenized by vortexing in 1 mL of sterile PBS, allowed to settle for 10 minutes at RT, and the resulting supernatants were serially diluted up to 10^{-6} . The dilutions were plated on LB-Kan⁺ agar plates and incubated at 37°C overnight. To quantify fecal *S. Typhimurium* burden by qPCR, the *STM4497* gene was measured and normalized to total *Eubacteria*, using *E. coli* DNA to generate the standard curve. Primer sequences used are following: *STM* forward: AACACGGCTCCGGTAATGAGATTG; *STM* reverse ATGACAACTCTTGATTCTGAAGATCG; *Eubacteria* forward: CGGCAACGACGCCAACCC; *Eubacteria* reverse: CCATTGTAGCACGTGTGTAGCC.

RT-qPCR analysis

IEL and LP lymphocytes were isolated as described above and sorted on a BD FACS Aria II instrument. Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, Inc.) according to the manufacturer's protocol. Complementary DNA (cDNA) was synthesized from 1 μ g of RNA with iScript™ cDNA Synthesis Kit (Bio-Rad).

Quantitative PCR (qPCR) was performed with iTaq Universal SYBR Green Supermix (Bio-Rad) on the CFX Connect Real-Time System (Biorad). The expression of target genes was normalized to the expression of the housekeeping gene *GAPDH* and quantified using the $2^{-\Delta\Delta Ct}$ method. The following primers were used: *Lingo4* forward: ACTCAGACACACGGGGAAGGTG; *Lingo4* reverse: GGGTCTGGGAGGTGCAGTCAC; *GAPDH* forward: CATCACTGCCACCCAGAAGACTG; *GAPDH* reverse: ATGCCAGTGAGCTTCCCGTTCAG.

Histological analysis of the intestinal tissue

Intestinal tissues were harvested, washed with cold PBS, opened longitudinally and pinned out. The tissues were fixed in 10% neutral buffered formalin solution (MilliporeSigma) overnight, followed by washing in 70% ethanol and embedding in 2% agar (MilliporeSigma). Tissues were paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E) or Alcian Blue/PAS. Stained tissue slides were scanned using the NanoZoomer-SQ Digital Slide Scanner (C13140-01; Hamamatsu Photonics K.K.). Histopathological evaluation of H&E-stained sections was performed using a 0-30 scoring system, based on the sum of 10 parameters rated from 0 (normal) to 3 (severe). The frequency of goblet cells in Alcian Blue/PAS-stained sections was assessed using a scale from 0 (absence) to 3 (enrichment). All scoring was performed by an investigator blinded to the experimental groups.

Fecal lipocalin-2 quantification

Fecal samples were reconstituted in sterile PBS with 0.1% Tween 20 at concentration of 50 mg/mL, vigorously vortexed for 20 seconds, followed by centrifugation at 8000 x g for 10 minutes. Lipocalin-2 levels were quantified using a Mouse Lipocalin-2/NGAL DuoSet ELISA kit (R&D Systems). Supernatants were diluted 4-fold to 100-fold and absorbance was measured at 450 nm using BioTek Synergy H1 Plate Reader (Vermont, USA).

Analysis of FITC-dextran in the serum

Mice were given 0.25 mg/g of Fluorescein isothiocyanate-dextran (FITC-dextran; 4 kDa; Sigma-Aldrich) solution in 200 μ L PBS by oral gavage. After 4h, during which mice were deprived of food and water, mice were anesthetized, and blood was collected by cardiac puncture. Presence of FITC-dextran in the serum was analyzed by spectrophotometric measurement on BioTek Synergy H1 Plate Reader (Vermont, USA) at 485/528 nm (excitation/emission). A standard curve was generated with serial dilutions of 100 μ g/mL FITC-Dextran in PBS.

In vivo antibody treatment

Uninfected, *S. Typhimurium* or *C. rodentium* infected mice were i.p. injected with 150 μ g anti-mouse IL-22 neutralizing antibody (clone 8E11; Genentech), 150 μ g isotype control IgG2a (BioXcell) or 1 μ g recombinant mouse IL-22 protein (Proteintech) in 100 μ L sterile PBS at indicated time points.

Bacterial 16S rRNA quantification

Total DNA was extracted from the liver, mesenteric lymph nodes or fecal pellets of infected mice using the DNeasy Blood & Tissue Kit (Qiagen) per the manufacturer's instructions. Bacterial DNA levels were quantified by qPCR with iTaq Universal SYBR Green Supermix (Bio-Rad) using primers targeting the 16S rRNA gene V4 region (forward: CGGCAACGACGCCAACCC; reverse: CCATTGTAGCACGTGTGTAGCC). Bacterial load was calculated using a standard curve based on serial dilutions of *Escherichia coli* genomic DNA and expressed as 16S rRNA gene copies per gram.

Immunofluorescence

293T or 293T-Lingo4 cells were grown on coverslips overnight, washed in PBS and fixed in 4% paraformaldehyde for 20 min at RT. Blocking and permeabilization step was conducted in PBS containing 2% BSA and 0.1% Triton X-100 for 1 hour at RT. Cells were incubated with anti-FLAG antibody (Rockland, #200-310-B13) for 2 h at RT, followed by 1 h incubation with Alexa-fluor-647 goat anti-mouse IgG (H+L) (A-21236, Invitrogen). Nuclear staining was conducted using DAPI solution (NBP2-31156, Novus Bio) for 10 min at RT. Coverslips were mounted with ProLongTM Glass Antifade Mountant (Invitrogen). Fluorescence images were acquired using Zeiss LSM880 Confocal Laser Scanning Microscope with Airyscan. Image analysis was performed in Fiji.

Transmission electron microscopy (TEM)

ILC3s were isolated from LP as described above and sort purified on a BD FACS Aria II instrument. The cell pellet was fixed in freshly prepared 2% PFA/2.5% glutaraldehyde (Ted Pella, Inc., Redding, CA) in 100 mM sodium cacodylate buffer (pH 7.2) for 2 hours at RT. Samples were washed in sodium cacodylate buffer, post-fixed in 1% osmium tetroxide (Ted Pella, Inc.) for 1 hour and thoroughly rinsed in dH₂O before en bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc.) for 1 hour. Following additional dH₂O rinses, samples were dehydrated through a graded ethanol series and embedded in Eponate 12 resin (Ted Pella Inc.). Ultrathin sections (95 nm) were cut using a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL) and collected on Cu grids, and stained with uranyl acetate and lead citrate. Imaging was performed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8-megapixel digital camera and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques, Woburn, MA). TEM analysis included at least 20 cells per sample.

Bulk RNA sequencing of ILC3s

ILC3s were isolated from LP of WT and *Lingo4*^{-/-} mice as described above, and sort purified on BD FACS Aria II cell sorter. Total RNA was extracted using RNeasy Mini Kits (Qiagen) per manufacturer's instructions. Total RNA integrity was determined using Agilent Bioanalyzer or 4200 TapeStation. Library preparation was performed using SMARTer Ultra Low RNA kit for Illumina Sequencing (Takara-Clontech) per manufacturer's protocol. Samples were indexed, pooled, and sequenced on an Illumina NovaSeq 6000. Base calls and demultiplexing were performed with Illumina's bcl2fastq software and a custom python demultiplexing program with a maximum of one mismatch in the indexing read. RNA-seq

reads were then aligned to the Ensembl release 76 primary assembly with STAR version 2.5.1a. Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.6-p5. Gene count tables were processed and analyzed in R using the DESeq2 package. Before performing differential expression analysis, genes with fewer than 10 total counts across all samples were removed. Gene ontology enrichment analysis of differentially expressed genes ($\text{padj} < 0.01$) was carried out using Metascape (Zhou et al., 2019).

Microbiota metataxonomic analysis

Fecal samples were collected into sterile, DNA-free tubes, immediately frozen, and stored at -80°C . Microbial DNA was extracted using the PureLink Microbiome DNA Purification Kit (Thermo Fisher Scientific). Library preparation and paired-end 250 bp sequencing were performed at the Genome Access Technology Center (GTAC) at the McDonnell Genome Institute, Washington University in St. Louis, USA, on an Illumina NovaSeq 6000 platform. Raw FASTQ files from both experiments were processed with nf-core/ampliseq v2.12.0, part of the nf-core workflow collection, using reproducible environments provided by Bioconda and Biocontainers. Read quality was assessed with FastQC and summarized using MultiQC. Amplicon sequence variants (ASVs) were inferred sample-wise using DADA2 (Callahan et al., 2016). Processing included removal of PhiX reads, trimming based on quality (forward and reverse reads truncated at 151 bp; reads shorter than this discarded), filtering reads with >2 expected errors, error correction, merging of paired-end reads, and chimera removal. For experiment 1 (WT vs. *Lingo4*^{-/-} $\pm$ cohousing), DADA2 identified 6,610 ASVs, retaining 30.28-38.55% of reads per sample (mean 35%), corresponding to 2,450,356 total reads (130,844-167,614 per sample; mean 153,147). For experiment 2 (WT vs. *Lingo4*^{-/-} at days -27, 0, 7, and 21), DADA2 identified 7,285 ASVs, retaining 27.8-60.48% of reads per sample (mean 42.7%), corresponding to 2,876,130 total reads (130-199,286 per sample; mean 119,839). Taxonomic assignment for both datasets was performed using the SILVA v138 reference database. Representative sequences, ASV abundance tables, and taxonomy files were imported into QIIME2 (Bolyen et al., 2019). ASVs annotated as mitochondria, chloroplasts, or archaea were removed (41 removed in experiment 1; 37 removed in experiment 2), resulting in 6,569 and 7,248 ASVs, respectively, used for downstream analyses. Phylogenetic placement was performed using the SEPP fragment-insertion method with the SILVA 128 backbone, and taxonomic composition was refined using the q2-feature-classifier pretrained on SILVA 138 (99% OTUs, full-length sequences). All downstream analyses were performed in R using phyloseq, microViz, and MicrobiotaProcess. Alpha diversity was calculated using the Shannon index, and beta diversity was assessed using Bray-Curtis and unweighted UniFrac distances. Community composition, ordination plots, and taxa-level visualizations were generated with these packages. Microbiome analyses and visualization were performed in R using phyloseq (McMurdie and Holmes, 2013), microViz, and MicrobiotaProcess (Xu et al., 2023). Differential abundance testing was conducted using MaAsLin2 (Multivariate Association with Linear Models 2) and LEfSe (Linear Discriminant Analysis Effect Size). Functional potential was inferred using PICRUSt2 (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States), producing predicted MetaCyc pathways and KEGG orthologs for downstream interpretation.

Immunoprecipitation and mass spectrometry

293T cells expressing Lingo4 with N-terminal FLAG and C-terminal 6xHis tag were lysed in cell lysis buffer (#9803, Cell Signaling) with added PMSF (#8553, Cell Signaling) for 30 min on ice, followed by centrifugation at 14000 rpm for 10 min to collect soluble fraction. G-protein agarose beads (Sigma Aldrich) were incubated with anti-FLAG antibody (Rockland) at concentration of 10 µg/mL in PBS for 4h at 4°C with rotation. Pre-clearing of cell lysates was performed by incubation of lysates with non-coated G-protein agarose beads for 3h with rotation at 4°C. Immunoprecipitation was conducted with anti-FLAG antibody-coated G-protein agarose beads at 4°C with rotation overnight, followed by centrifugation and washing of beads in PBS. Samples were processed using EasyPep Mini MS Sample Prep Kit (Thermo Fisher Scientific) with the following modifications: beads were washed with 100 µL 20 mM ammonium bicarbonate three times before proceeding with EasyPep Mini MS Sample Prep Kit; samples were reduced and alkylated for 30 min at 40°C, followed by 10 min at 95°C; and samples were digested overnight at 37°C with shaking (900 rpm). The extracted peptides were dried down and resuspended in water with 0.1% formic acid for LC-MS analysis. LC-MS was performed with a Dionex RSLCnano HPLC coupled to an Orbitrap Fusion Lumos (Thermo Fisher Scientific) mass spectrometer using a 115 min gradient (1-90% acetonitrile) and 25 min re-equilibration. Sample was resolved using a 75 µm x 15 cm PepMap C18 column (Thermo Scientific) and a 75 µm x 2 cm trap column with matching stationary phase used in flowthrough configuration. Sample data were analyzed using Proteome Discoverer 2.4 (Thermo Scientific). Thermo .raw files were processed using the “Spectrum Files RC” and “Spectrum Selector” nodes. Protein identifications were accepted if they could be established at greater than 99.0% probability. Gene ontology analysis was conducted on proteins present in 239T-Lingo4 cells but not control cells, and with ≥10% of coverage using Metascape (Zhou et al., 2019).

Statistical analysis

Statistical analyses were conducted using GraphPad Prism version 10.0 (San Diego, CA, USA). Survival data were analyzed using Kaplan-Meier curves and compared using the log-rank test. Normality of data distribution was assessed using the Shapiro-Wilk test, and variance homogeneity was evaluated using appropriate tests. For normally distributed datasets, two-group comparisons were performed using two-tailed unpaired Student's t-tests, and comparisons across multiple groups were assessed using one-way ANOVA followed by Tukey's post hoc test. For non-normally distributed data, Mann-Whitney U tests were used for two-group comparisons, and the Kruskal-Wallis test with Dunn's post hoc test was applied for comparisons involving more than two groups. Data are presented as mean ± standard error of the mean (SEM). Statistical significance thresholds were defined as *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$; ns = not significant.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would like to thank the Flow Cytometry & Fluorescence Activated Cell Sorting Core, the Digestive Diseases Research Core Center (DDRCC), the Alafi Neuroimaging Laboratory (supported by an NIH Shared Instrumentation grant S10 OD032131), the Molecular Microbiology Imaging Facility, and the Immunomonitoring Laboratory at the Bursky Center for Human Immunology and Immunotherapy Programs (supported by the Rheumatic Diseases Core Center, NIH WLC6313040077) at Washington University School of Medicine. We thank the Genome Technology Access Center in the Department of Genetics at Washington University School of Medicine for help with genomic analysis. The Center is partially supported by NCI Cancer Center Support Grant #P30 CA91842 to the Siteman Cancer Center and by ICTS/CTSA Grant# UL1TR000448 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. We thank the Bioanalytical Chemistry Facility at the Danforth Plant Science Center supported by the National Science Foundation under Grant No. DBI-1827534 for acquisition of the Orbitrap Fusion Lumos LC-MS/MS.

This study was supported by the National Institutes of Health, USA (R01DK126969; R01DK132327), the Pew Charitable Trusts, USA (00035299), and the São Paulo Research Foundation, Brazil (FAPESP 2017/06577-9; 2023/00393-4).

Data availability

Bulk RNA and 16S rRNA gene sequencing data generated in this study have been deposited in the Gene Expression Omnibus (GEO) and are publicly available (GSE325926 and PRJNA1442760, respectively). Additional data and materials supporting the findings are available from the corresponding author upon reasonable request.

Non-standard abbreviations

AHR	Aryl hydrocarbon receptor
DN (ILC3s)	Double-negative (NKp46 ⁻ CCR6 ⁻) group 3 innate lymphoid cells
FMT	Fecal microbiota transplantation
IECs	Intestinal epithelial cells
ILC	Innate lymphoid cell
ILC3	Group 3 innate lymphoid cell
LINGO4	Leucine-rich repeat and immunoglobulin-like domain-containing protein 4
mROS	Mitochondrial reactive oxygen species
pTreg	Peripherally induced regulatory T cell
RORγt	Retinoic acid receptor-related orphan receptor gamma t
SCFA	Short-chain fatty acid
siLP	Small intestinal lamina propria
STAT3	Signal transducer and activator of transcription 3
VNAM	Vancomycin, neomycin, ampicillin, and metronidazole

References

- Abt MC, Lewis BB, Caballero S, Xiong H, Carter RA, Sušac B, Ling L, Leiner I, and Pamer EG. 2015. Innate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute *Clostridium difficile* Infection. *Cell Host Microbe*. 18:27–37. doi:10.1016/j.chom.2015.06.011. [PubMed: 26159718]
- Abt MC, McKenney PT, and Pamer EG. 2016. *Clostridium difficile* colitis: pathogenesis and host defence. *Nat. Rev. Microbiol* 14:609–20. doi:10.1038/nrmicro.2016.108. [PubMed: 27573580]
- Behnsen J, Jellbauer S, Wong CP, Edwards RA, George MD, Ouyang W, and Raffatellu M. 2014. The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. *Immunity*. 40:262–73. doi:10.1016/j.immuni.2014.01.003. [PubMed: 24508234]
- Belle NM, Ji Y, Herbine K, Wei Y, Park J, Zullo K, Hung L-Y, Srivatsa S, Young T, Oniskey T, Pastore C, Nieves W, Somsouk M, and Herbert DR. 2019. TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths. *Nat. Commun* 10:4408. doi:10.1038/s41467-019-12315-1. [PubMed: 31562318]
- Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown CT, Callahan BJ, Caraballo-Rodríguez AM, Chase J, Cope EK, Da Silva R, Diener C, Dorrestein PC, Douglas GM, Durall DM, Duvallet C, Edwardsen CF, Ernst M, Estaki M, Fouquier J, Gauglitz JM, Gibbons SM, Gibson DL, Gonzalez A, Gorlick K, Guo J, Hillmann B, Holmes S, Holste H, Huttenhower C, Huttley GA, Janssen S, Jarmusch AK, Jiang L, Kaehler BD, Bin Kang K, Keefe CR, Keim P, Kelley ST, Knights D, Koester I, Kosciulek T, Kreps J, Langille MGI, Lee J, Ley R, Liu Y-X, Loftfield E, Lozupone C, Maher M, Marotz C, Martin BD, McDonald D, McIver LJ, V Melnik A, Metcalf JL, Morgan SC, Morton JT, Naimey AT, Navas-Molina JA, Nothias LF, Orchanian SB, Pearson T, Peoples SL, Petras D, Preuss ML, Priesse E, Rasmussen LB, Rivers A, Robeson MS, Rosenthal P, Segata N, Shaffer M, Shiffer A, Sinha R, Song SJ, Spear JR, Swofford AD, Thompson LR, Torres PJ, Trinh P, Tripathi A, Turnbaugh PJ, Ul-Hasan S, van der Hoof JJJ, Vargas F, Vázquez-Baeza Y, Vogtmann E, et al. 2019. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat. Biotechnol* 37:852–857. doi:10.1038/s41587-019-0209-9. [PubMed: 31341288]
- Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, and Powrie F. 2010. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. *Nature*. 464:1371–5. doi:10.1038/nature08949. [PubMed: 20393462]
- Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, and Holmes SP. 2016. DADA2: High-resolution sample inference from Illumina amplicon data. *Nat. Methods* 13:581–3. doi:10.1038/nmeth.3869. [PubMed: 27214047]
- Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JKM, Doherty JM, Mills JC, and Colonna M. 2009. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. *Nature*. 457:722–5. doi:10.1038/nature07537. [PubMed: 18978771]
- Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, and Kelly CP. 2008. A Mouse Model of *Clostridium difficile*-Associated Disease. *Gastroenterology*. 135:1984–1992. doi:10.1053/j.gastro.2008.09.002. [PubMed: 18848941]
- Chun E, Lavoie S, Fonseca-Pereira D, Bae S, Michaud M, Hoveyda HR, Fraser GL, Gallini Comeau CA, Glickman JN, Fuller MH, Layden BT, and Garrett WS. 2019. Metabolite-Sensing Receptor Ffar2 Regulates Colonic Group 3 Innate Lymphoid Cells and Gut Immunity. *Immunity*. 51:871–884.e6. doi:10.1016/j.immuni.2019.09.014. [PubMed: 31628054]
- Clay SL, Bravo-Blas A, Wall DM, MacLeod MKL, and Milling SWF. 2020. Regulatory T cells control the dynamic and site-specific polarization of total CD4 T cells following *Salmonella* infection. *Mucosal Immunol*. 13:946–957. doi:10.1038/s41385-020-0299-1. [PubMed: 32457450]
- Collins JW, Keeney KM, Crepin VF, Rathinam VAK, Fitzgerald KA, Finlay BB, and Frankel G. 2014. *Citrobacter rodentium*: infection, inflammation and the microbiota. *Nat. Rev. Microbiol* 12:612–623. doi:10.1038/nrmicro3315. [PubMed: 25088150]
- Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, Grogan JL, Fibbe WE, Cornelissen JJ, and Spits H. 2009. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing

- precursors to RORC+ CD127+ natural killer-like cells. *Nat. Immunol* 10:66–74. doi:10.1038/ni.1668. [PubMed: 19029905]
- Dudem S, Large RJ, Kulkarni S, McClafferty H, Tikhonova IG, Sergeant GP, Thornbury KD, Shipston MJ, Perrino BA, and Hollywood MA. 2020. LINGO1 is a regulatory subunit of large conductance, Ca²⁺-activated potassium channels. *Proc. Natl. Acad. Sci. U. S. A* 117:2194–2200. doi:10.1073/pnas.1916715117. [PubMed: 31932443]
- Eberl G, Colonna M, Di Santo JP, and McKenzie ANJ. 2015. Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. *Science*. 348:aaa6566. doi:10.1126/science.aaa6566. [PubMed: 25999512]
- Eberl G, Marmon S, Sunshine M-J, Rennert PD, Choi Y, and Littman DR. 2004. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. *Nat. Immunol* 5:64–73. doi:10.1038/ni1022. [PubMed: 14691482]
- Fachi JL, Di Luccia B, Gilfillan S, Chang H-W, Song C, Cheng J, Cella M, Vinolo MA, Gordon JI, and Colonna M. 2024. Deficiency of IL-22-binding protein enhances the ability of the gut microbiota to protect against enteric pathogens. *Proc. Natl. Acad. Sci. U. S. A* 121:e2321836121. doi:10.1073/pnas.2321836121. [PubMed: 38687788]
- Fachi JL, de Oliveira S, Trsan T, Penati S, Gilfillan S, Cao S, Ribeiro Castro P, Fernandes MF, Hyrc KL, Liu X, Rodrigues PF, Bhattarai B, Layden BT, Vinolo MAR, and Colonna M. 2025. Fiber- and acetate-mediated modulation of MHC-II expression on intestinal epithelium protects from *Clostridioides difficile* infection. *Cell Host Microbe*. 33:235–251.e7. doi:10.1016/j.chom.2024.12.017. [PubMed: 39826540]
- Fachi JL, Sécca C, Rodrigues PB, de Mato FCP, Di Luccia B, Felipe J. de S., Pral LP, Rungue M, Rocha V. de M., Sato FT, Sampaio U, Clerici MTPS, Rodrigues HG, Câmara NOS, Consonni SR, Vieira AT, Oliveira SC, Mackay CR, Layden BT, Bortoluci KR, Colonna M, and Vinolo MAR. 2020. Acetate coordinates neutrophil and ILC3 responses against *C. difficile* through FFAR2. *J. Exp. Med* 217. doi:10.1084/jem.20190489.
- Faria AMC, Reis BS, and Mucida D. 2017. Tissue adaptation: Implications for gut immunity and tolerance. *J. Exp. Med* 214:1211–1226. doi:10.1084/jem.20162014. [PubMed: 28432200]
- Fonseca-Pereira D, Bae S, Clay SL, Michaud M, MacDonald MH, Glickman JN, and Garrett WS. 2025. The metabolic sensor LKB1 regulates ILC3 homeostasis and mitochondrial function. *Cell Rep*. 44:115456. doi:10.1016/j.celrep.2025.115456. [PubMed: 40120107]
- Grizotte-Lake M, Zhong G, Duncan K, Kirkwood J, Iyer N, Smolenski I, Isoherranen N, and Vaishnav S. 2018. Commensals Suppress Intestinal Epithelial Cell Retinoic Acid Synthesis to Regulate Interleukin-22 Activity and Prevent Microbial Dysbiosis. *Immunity*. 49:1103–1115.e6. doi:10.1016/j.immuni.2018.11.018. [PubMed: 30566883]
- Guillemain A, Laouarem Y, Cobret L, Štefok D, Chen W, Bloch S, Zahaf A, Blot L, Reverchon F, Normand T, Decoville M, Grillon C, Traiffort E, and Morisset-Lopez S. 2020. LINGO family receptors are differentially expressed in the mouse brain and form native multimeric complexes. *FASEB J*. 34:13641–13653. doi:10.1096/fj.202000826R. [PubMed: 32862444]
- Guo X, Qiu J, Tu T, Yang X, Deng L, Anders RA, Zhou L, and Fu Y-X. 2014. Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection. *Immunity*. 40:25–39. doi:10.1016/j.immuni.2013.10.021. [PubMed: 24412612]
- Gury-BenAri M, Thaïs CA, Serafini N, Winter DR, Giladi A, Lara-Astiaso D, Levy M, Salame TM, Weiner A, David E, Shapiro H, Dori-Bachash M, Pevsner-Fischer M, Lorenzo-Vivas E, Keren-Shaul H, Paul F, Harmelin A, Eberl G, Itzkovitz S, Tanay A, Di Santo JP, Elinav E, and Amit I. 2016. The Spectrum and Regulatory Landscape of Intestinal Innate Lymphoid Cells Are Shaped by the Microbiome. *Cell*. 166:1231–1246.e13. doi:10.1016/j.cell.2016.07.043. [PubMed: 27545347]
- Haines BP, and Rigby PWJ. 2008. Expression of the Lingo/LERN gene family during mouse embryogenesis. *Gene Expr. Patterns* 8:79–86. doi:10.1016/j.modgep.2007.10.003. [PubMed: 18297755]
- He YW, Deftos ML, Ojala EW, and Bevan MJ. 1998. RORgamma t, a novel isoform of an orphan receptor, negatively regulates Fas ligand expression and IL-2 production in T cells. *Immunity*. 9:797–806. doi:10.1016/s1074-7613(00)80645-7. [PubMed: 9881970]

- Heng TSP, Painter MW, and Immunological Genome Project Consortium. 2008. The Immunological Genome Project: networks of gene expression in immune cells. *Nat. Immunol* 9:1091–4. doi:10.1038/ni1008-1091. [PubMed: 18800157]
- Horn V, and Sonnenberg GF. 2024. Group 3 innate lymphoid cells in intestinal health and disease. *Nat. Rev. Gastroenterol. Hepatol* 21:428–443. doi:10.1038/s41575-024-00906-3. [PubMed: 38467885]
- Hou Q, Huang J, Xiong X, Guo Y, and Zhang B. 2022. Role of Nutrient-sensing Receptor GPRC6A in Regulating Colonic Group 3 Innate Lymphoid Cells and Inflamed Mucosal Healing. *J. Crohns Colitis* 16:1293–1305. doi:10.1093/ecco-jcc/jjac020. [PubMed: 35134872]
- Inoue H, Lin L, Lee X, Shao Z, Mendes S, Snodgrass-Belt P, Sweigard H, Engber T, Pepinsky B, Yang L, Beal MF, Mi S, and Isacson O. 2007. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. *Proc. Natl. Acad. Sci. U. S. A* 104:14430–5. doi:10.1073/pnas.0700901104. [PubMed: 17726113]
- Jarade A, Garcia Z, Marie S, Demera A, Prinz I, Bousso P, Di Santo JP, and Serafini N. 2022. Inflammation triggers ILC3 patrolling of the intestinal barrier. *Nat. Immunol* 23:1317–1323. doi:10.1038/s41590-022-01284-1. [PubMed: 35999393]
- Kabil AK, Liu LT, Xu C, Nayyar N, González L, Chopra S, Brassard J, Beaulieu M-J, Li Y, Damji A, Zandstra PW, Blanchet M-R, Hughes MR, and McNagny KM. 2025. Microbial dysbiosis sculpts a systemic ILC3/IL-17 axis governing lung inflammatory responses and central hematopoiesis. *Mucosal Immunol.* 18:1139–1158. doi:10.1016/j.mucimm.2025.07.002. [PubMed: 40695364]
- Kiss EA, Vonarbourg C, Kopfmann S, Hobeika E, Finke D, Esser C, and Diefenbach A. 2011. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. *Science*. 334:1561–5. doi:10.1126/science.1214914. [PubMed: 22033518]
- Klose CSN, and Artis D. 2016. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. *Nat. Immunol* 17:765–74. doi:10.1038/ni.3489. [PubMed: 27328006]
- Lee JS, Cella M, McDonald KG, Garlanda C, Kennedy GD, Nukaya M, Mantovani A, Kopan R, Bradfield CA, Newberry RD, and Colonna M. 2011. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. *Nat. Immunol* 13:144–51. doi:10.1038/ni.2187. [PubMed: 22101730]
- Lehmann FM, von Burg N, Ivanek R, Teufel C, Horvath E, Peter A, Turchinovich G, Staehli D, Eichlisberger T, Gomez de Agüero M, Coto-Llerena M, Prchal-Murphy M, Sexl V, Bentires-Alj M, Mueller C, and Finke D. 2020. Microbiota-induced tissue signals regulate ILC3-mediated antigen presentation. *Nat. Commun* 11:1794. doi:10.1038/s41467-020-15612-2. [PubMed: 32286285]
- Li N, van Unen V, Höllt T, Thompson A, van Bergen J, Pezzotti N, Eisemann E, Vilanova A, Chuva de Sousa Lopes SM, Lelieveldt BPF, and Koning F 2018. Mass cytometry reveals innate lymphoid cell differentiation pathways in the human fetal intestine. *J. Exp. Med* 215:1383–1396. doi:10.1084/jem.20171934. [PubMed: 29511064]
- Liang SC, Tan X-Y, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, and Fouser LA. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. *J. Exp. Med* 203:2271–9. doi:10.1084/jem.20061308. [PubMed: 16982811]
- Lo BC, Canals Hernaez D, Scott RW, Hughes MR, Shin SB, Underhill TM, Takei F, and McNagny KM. 2019. The Transcription Factor RORα Preserves ILC3 Lineage Identity and Function during Chronic Intestinal Infection. *J. Immunol* 203:3209–3215. doi:10.4049/jimmunol.1900781. [PubMed: 31676672]
- Di Luccia B, Gilfillan S, Cella M, Colonna M, and Huang SC-C. 2019. ILC3s integrate glycolysis and mitochondrial production of reactive oxygen species to fulfill activation demands. *Journal of Experimental Medicine*. 216:2231–2241. doi:10.1084/jem.20180549. [PubMed: 31296736]
- McMurdie PJ, and Holmes S. 2013. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. *PLoS One*. 8:e61217. doi:10.1371/journal.pone.0061217. [PubMed: 23630581]
- Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q, Wong WM, Wang L, Su H, Chu T-H, Guo J, Zhang W, So K-F, Pepinsky B, Shao Z, Graff C, Garber E, Jung V, Wu EX, and Wu W. 2007. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in

- MOG-induced experimental autoimmune encephalomyelitis. *Nat. Med* 13:1228–33. doi:10.1038/nm1664. [PubMed: 17906634]
- van de Pavert SA, Ferreira M, Domingues RG, Ribeiro H, Molenaar R, Moreira-Santos L, Almeida FF, Ibiza S, Barbosa I, Goverse G, Labão-Almeida C, Godinho-Silva C, Konijn T, Schooneman D, O'Toole T, Mizze MR, Habani Y, Haak E, Santori FR, Littman DR, Schulte-Merker S, Dzierzak E, Simas JP, Mebius RE, and Veiga-Fernandes H. 2014. Maternal retinoids control type 3 innate lymphoid cells and set the offspring immunity. *Nature*. 508:123–7. doi:10.1038/nature13158. [PubMed: 24670648]
- Pedicord VA, Lockhart AAK, Rangan KJ, Craig JW, Loschko J, Rogoz A, Hang HC, and Mucida D. 2016. Exploiting a host-commensal interaction to promote intestinal barrier function and enteric pathogen tolerance. *Sci. Immunol* 1. doi:10.1126/sciimmunol.aai7732.
- Pral LP, Fachi JL, Corrêa RO, Colonna M, and Vinolo MAR. 2021. Hypoxia and HIF-1 as key regulators of gut microbiota and host interactions. *Trends Immunol*. 42:604–621. doi:10.1016/j.it.2021.05.004. [PubMed: 34171295]
- Reynders A, Yessaad N, Vu Manh T-P, Dalod M, Fenis A, Aubry C, Nikitas G, Escalière B, Renaud JC, Dussurget O, Cossart P, Lecuit M, Vivier E, and Tomasello E. 2011. Identity, regulation and in vivo function of gut NKp46+ROR γ t+ and NKp46+ROR γ t-lymphoid cells. *EMBO J*. 30:2934–47. doi:10.1038/emboj.2011.201. [PubMed: 21685873]
- Rodrigues PF, Wu S, Trsan T, Panda SK, Fachi JL, Liu Y, Du S, de Oliveira S, Antonova AU, Khantakova D, Sudan R, Desai P, Diamond MS, Gilfillan S, Anderson SK, Cella M, and Colonna M. 2025. Ror γ t-positive dendritic cells are required for the induction of peripheral regulatory T cells in response to oral antigens. *Cell*. 188:2720–2737.e22. doi:10.1016/j.cell.2025.03.020. [PubMed: 40185101]
- Sabihi M, Böttcher M, Pelczar P, and Huber S. 2020. Microbiota-Dependent Effects of IL-22. *Cells*. 9. doi:10.3390/cells9102205.
- Sanos SL, Bui VL, Mortha A, Oberle K, Heners C, Johnner C, and Diefenbach A. 2009. ROR γ and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. *Nat. Immunol* 10:83–91. doi:10.1038/ni.1684. [PubMed: 19029903]
- Satoh-Takayama N, Vosschenrich CAJ, Lesjean-Pottier S, Sawa S, Lochner M, Rattis F, Mention J-J, Thiam K, Cerf-Bensussan N, Mandelboim O, Eberl G, and Di Santo JP. 2008. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. *Immunity*. 29:958–70. doi:10.1016/j.immuni.2008.11.001. [PubMed: 19084435]
- Sawa S, Cherrier M, Lochner M, Satoh-Takayama N, Fehling HJ, Langa F, Di Santo JP, and Eberl G. 2010. Lineage relationship analysis of ROR γ innate lymphoid cells. *Science*. 330:665–9. doi:10.1126/science.1194597. [PubMed: 20929731]
- Serafini N, Vosschenrich CAJ, and Di Santo JP. 2015. Transcriptional regulation of innate lymphoid cell fate. *Nat. Rev. Immunol* 15:415–28. doi:10.1038/nri3855. [PubMed: 26065585]
- Sonnenberg GF, Fouser LA, and Artis D. 2011. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. *Nat. Immunol* 12:383–90. doi:10.1038/ni.2025. [PubMed: 21502992]
- Sun Z, Unutmaz D, Zou YR, Sunshine MJ, Pierani A, Brenner-Morton S, Mebius RE, and Littman DR. 2000. Requirement for ROR γ in thymocyte survival and lymphoid organ development. *Science*. 288:2369–73. doi:10.1126/science.288.5475.2369. [PubMed: 10875923]
- Teufel C, Horvath E, Peter A, Ercan C, Piscuoglio S, Hall MN, Finke D, and Lehmann FM. 2021. mTOR signaling mediates ILC3-driven immunopathology. *Mucosal Immunol*. 14:1323–1334. doi:10.1038/s41385-021-00432-4. [PubMed: 34341503]
- van der Velden AWM, Copass MK, and Starnbach MN. 2005. Salmonella inhibit T cell proliferation by a direct, contact-dependent immunosuppressive effect. *Proc. Natl. Acad. Sci. U. S. A* 102:17769–74. doi:10.1073/pnas.0504382102. [PubMed: 16306269]
- Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie ANJ, Mebius RE, Powrie F, and Spits H. 2018. Innate Lymphoid Cells: 10 Years On. *Cell*. 174:1054–1066. doi:10.1016/j.cell.2018.07.017. [PubMed: 30142344]
- Walker GT, Gerner RR, Nuccio S-P, and Raffatellu M. 2023. Murine Models of Salmonella Infection. *Curr. Protoc* 3:e824. doi:10.1002/cpz1.824. [PubMed: 37478288]

- Wang R, Cui W, and Yang H. 2023. The interplay between innate lymphoid cells and microbiota. *mBio*. 14:e0039923. doi:10.1128/mbio.00399-23. [PubMed: 37318214]
- Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, Chen SG, Perry G, Casadesus G, and Zhu X. 2012. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. *Hum. Mol. Genet* 21:1931–44. doi:10.1093/hmg/dd003. [PubMed: 22228096]
- Weindel CG, Bell SL, Vail KJ, West KO, Patrick KL, and Watson RO. 2020. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to *Mycobacterium tuberculosis*. *Elife*. 9. doi:10.7554/eLife.51071.
- Wu D, Hu L, Han M, Deng Y, Zhang Y, Ren G, Zhao X, Li Z, Li P, Zhang Y, Chen S, Li J, Shi Y, Xue J, Wang P, and Zhong C. 2022. PD-1 signaling facilitates activation of lymphoid tissue inducer cells by restraining fatty acid oxidation. *Nat. Metab* 4:867–882. doi:10.1038/s42255-022-00595-9. [PubMed: 35788761]
- Xiong L, Wang S, Dean JW, Oliff KN, Jobin C, Curtiss R, and Zhou L. 2022. Group 3 innate lymphoid cell pyroptosis represents a host defence mechanism against *Salmonella* infection. *Nat. Microbiol* 7:1087–1099. doi:10.1038/s41564-022-01142-8. [PubMed: 35668113]
- Xu S, Zhan L, Tang W, Wang Q, Dai Z, Zhou L, Feng T, Chen M, Wu T, Hu E, and Yu G. 2023. MicrobiotaProcess: A comprehensive R package for deep mining microbiome. *Innovation (Cambridge (Mass.))*. 4:100388. doi:10.1016/j.xinn.2023.100388. [PubMed: 36895758]
- Yu H, Jacquilot N, and Belz GT. 2022. Metabolic features of innate lymphoid cells. *J. Exp. Med* 219. doi:10.1084/jem.20221140.
- Zenewicz LA, Yin X, Wang G, Elinav E, Hao L, Zhao L, and Flavell RA. 2013. IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic. *J. Immunol* 190:5306–12. doi:10.4049/jimmunol.1300016. [PubMed: 23585682]
- Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas AR, Modrusan Z, Ghilardi N, de Sauvage FJ, and Ouyang W. 2008. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nat. Med* 14:282–9. doi:10.1038/nm1720. [PubMed: 18264109]
- Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, and Chanda SK. 2019. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat. Commun* 10:1523. doi:10.1038/s41467-019-09234-6. [PubMed: 30944313]
- Zhu Q, Korenfeld D, Suarez-Fueyo A, Graham S, Jin L, Punit S, Duffy R, Puri M, Caruso A, Hu C, Tian Y, McRae BL, Kamath R, Phillips L, Schwartz-Sterman AJ, Westmoreland S, Cao X, Levesque MC, Bi Y, Paez-Cortez J, and Goenka R. 2022. Epithelial dysfunction is prevented by IL-22 treatment in a *Citrobacter rodentium*-induced colitis model that shares similarities with inflammatory bowel disease. *Mucosal Immunol*. 15:1338–1349. doi:10.1038/s41385-022-00577-w. [PubMed: 36372810]
- Zindl CL, Wilson CG, Chadha AS, Duck LW, Cai B, Harbour SN, Nagaoka-Kamata Y, Hatton RD, Gao M, Figge DA, and Weaver CT. 2024. Distal colonocytes targeted by *C. rodentium* recruit T-cell help for barrier defence. *Nature*. 629:669–678. doi:10.1038/s41586-024-07288-1. [PubMed: 38600382]
- Zullo KM, Douglas B, Maloney NM, Ji Y, Wei Y, Herbine K, Cohen R, Pastore C, Cramer Z, Wang X, Wei W, Somsouk M, Hung LY, Lengner C, Kohanski MH, Cohen NA, and Herbert DR. 2021. LINGO3 regulates mucosal tissue regeneration and promotes TFF2 dependent recovery from colitis. *Scand. J. Gastroenterol* 56:791–805. doi:10.1080/00365521.2021.1917650. [PubMed: 33941035]




Figure 1. LINGO4 deficiency reduces ILC3 abundance and IL-22 production in a cell-intrinsic manner.

(A-C) Representative flow cytometry plots (A) and absolute numbers of ILCs in the small-intestinal (si) (B) and colonic (C) lamina propria (LP) of WT and *Lingo4*^{-/-} mice. Mean ± SEM, *n* = 7-12; pooled from three independent experiments. (D-E) Numbers of ILC3 subsets (NKp46⁺, CCR6⁺, and DN) in the siLP (D) and colon (E) of WT and *Lingo4*^{-/-} mice. Mean ± SEM, *n* = 7-12; pooled from four experiments. (F) Geometric mean fluorescence intensity (gMFI) of RORγt in ILC3s from siLP and colon of WT and *Lingo4*^{-/-} mice. Mean ± SEM, *n* = 6-7; two experiments combined. (G) Representative flow cytometry plots and frequencies of IL-22⁺ and IL-17⁺ siLP ILC3s after ex vivo stimulation

with IL-23 (10 ng/mL). Mean $\pm$ SEM, $n = 7$; two experiments combined. **(H)** Frequencies of IL-22⁺ cells across siLP ILC3 subsets after ex vivo stimulation with IL-23. Mean $\pm$ SEM, $n = 7$; two experiments combined. **(I)** Representative flow cytometry plots and frequencies of IL-22⁺ and IL-17⁺ colonic ILC3s after ex vivo stimulation with IL-23 (10 ng/mL). Mean $\pm$ SEM, $n = 9$; two experiments combined. **(J)** Mixed BM chimeras: irradiated CD45.1 recipients (1100 cGy) were reconstituted with a 1:1 mixture of CD45.1/2⁺ WT and CD45.2⁺ *Lingo4*^{-/-} BM cells. Representative reconstitution profile in spleen at 8 weeks. $n = 9$; two experiments combined. **(K-L)** Frequencies of WT (CD45.1/2⁺) and *Lingo4*^{-/-} (CD45.2⁺) ILC3s in siLP (K) and IL-22⁺ ILC3s following IL-23 stimulation (L). Mean $\pm$ SEM, $n = 9$ (K) and $n = 4$ (L); two experiments combined. **(M-N)** Representative flow cytometry plots and numbers of ILC3s (M) and ILC3 subsets (N) in siLP of *Lingo4*^{fl/fl} and *Lingo4* ^{Δ ILC3} mice. ILC3s were defined as live lymphocyte-sized Lin⁻ (CD3⁻ CD19⁻) Thy1.2^{hi} CD45^{int} cells. Mean $\pm$ SEM, $n = 4$; representative of two experiments. **(O)** Frequencies of IL-22⁺ and IL-17⁺ ILC3s after IL-23 stimulation. Mean $\pm$ SEM, $n = 4$; representative of two experiments. **(A-O)** Statistical significance was assessed using unpaired two-tailed *t*-tests or one-way ANOVA with Tukey's post hoc test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.




Figure 2. Reduced ILC3 responses in *Lingo4*^{-/-} mice depend on gut microbiota.

(A) Numbers of ILCs in siLP of cohoused *Lingo4*^{+/+}, *Lingo4*^{+/-}, and *Lingo4*^{-/-} littermates. Mean ± SEM, *n* = 9–11; three experiments combined. (B) Representative flow cytometry plots and frequencies of IL-22⁺ and IL-17⁺ ILC3s after IL-23 stimulation. Mean ± SEM, *n* = 4; representative of three experiments. (C–D) Antibiotic depletion of microbiota. VNAM treatment scheme and frequencies of ILC3s in non-cohoused VNAM-treated WT and *Lingo4*^{-/-} mice (C). IL-22⁺ and IL-17⁺ ILC3s after IL-23 stimulation (D). ILC3s were defined as live lymphocyte-sized Lin⁻ (CD3⁻ CD19⁻) Thy1.2^{hi} CD45^{int} cells. Mean ± SEM, *n* = 4; representative of two experiments. (E–G) Representative plots (E), numbers of ILC3s (F), and IL-22⁺ ILC3 frequencies following IL-23 stimulation (G) in WT and *Lingo4*^{-/-} mice at different ages. ILC3s were defined as live lymphocyte-sized Lin⁻ (CD3⁻ CD19⁻) Thy1.2^{hi} CD45^{int} cells. Mean ± SEM, *n* = 4–5. (H–I) Fecal microbiota composition analysis of co-housed and non-cohoused WT and *Lingo4*^{-/-} mice. Principal coordinates analysis (PCoA) of Bray–Curtis distances showing beta diversity; dot size indicates alpha

diversity (Shannon index) (H). Relative abundance at the family level (I). $n = 4$. **(A-G)**
Statistical significance was assessed using unpaired two-tailed t -tests or one-way ANOVA
with Tukey's post hoc test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3. Microbiota transplantation partially rescues the *Lingo4*^{-/-} ILC3 phenotype. (A-B) VNA pretreatment and FMT scheme (A) and total bacterial load measured by 16S rRNA gene copies across the FMT course (B). *n* = 3. (C-E) Frequencies of total ILC3s (C), IL-22⁺ ILC3s (D), and IL-17⁺ ILC3s (E) in siLP of WT and *Lingo4*^{-/-} mice after 3 weeks of FMT. Mean ± SEM, *n* = 3–4. (F-G) Bray-Curtis PCoA (F) and family-level fecal microbiota composition (G) of mice from (A). *n* = 4. “WT” refers to WT mice that received *Lingo4*^{-/-} microbiota, and “KO” refers to *Lingo4*^{-/-} mice that received WT microbiota. (H-I) Differentially enriched taxa in *Lingo4*^{-/-} (H) and WT (I) mice by LEfSe. *n* = 4. (A-E) Statistical significance was assessed using unpaired two-tailed *t*-tests or one-way ANOVA with Tukey’s post hoc test. *, *p* < 0.05; **, *p* < 0.01; ***, *p* < 0.001; **** *p* < 0.0001.




Figure 4. *Lingo4*^{-/-} mice are more susceptible to *C. rodentium* infection due to impaired IL-22-mediated mucosal protection.

(A) Body weight variation in cohoused and non-cohoused WT and *Lingo4*^{-/-} mice during *C. rodentium* infection. Mean $\pm$ SEM, $n = 15$; three experiments combined. (B) Fecal *C. rodentium* burden at 5, 10, 15, and 20 d.p.i. Mean $\pm$ SEM, $n = 9-11$; two experiments combined. (C-E) Colon length (C), fecal lipocalin-2 levels (D), and intestinal permeability by FITC-dextran (E) at 10 d.p.i. Mean $\pm$ SEM, $n = 9-11$ (C-D) and $n = 5$ (E). (F) Representative H&E sections of colon and small intestine with histopathological scoring

at 10 d.p.i. Mean $\pm$ SEM, $n = 5$. Scale bars = 100 μ m. **(G)** Representative plots and absolute numbers of myeloid cells in colon at 10 d.p.i. Mean $\pm$ SEM, $n = 5$; representative of two experiments. “NO”, neutrophils; “Mono”, monocytes; “Mac”, macrophages; “DC”, dendritic cells. **(H-I)** Representative plots and absolute numbers of siLP ILC3s (H) and IL-22⁺, IL-17⁺, and IFN- γ ⁺ siLP ILC3 (I) frequencies after ex vivo IL-23 stimulation at 10 d.p.i. Mean $\pm$ SEM, $n = 5$; representative of two experiments. ILC3s were defined as live lymphocyte-sized Lin⁻ (CD3⁻ CD19⁻) Thy1.2^{hi} CD45^{int} cells. **(J-K)** Representative plots and absolute numbers of colonic ILC3s (J) and IL-22⁺, IL-17⁺, and IFN- γ ⁺ colonic ILC3 (K) frequencies after ex vivo IL-23 stimulation at 10 d.p.i. Mean $\pm$ SEM, $n = 5$; representative of two experiments. ILC3s were defined as live lymphocyte-sized Lin⁻ (CD3⁻ CD19⁻) Thy1.2^{hi} CD45^{int} cells. **(L-N)** Schematic of IL-22 neutralization or recombinant IL-22 (rmIL-22) therapy during infection (L), relative body weight (M), and fecal *C. rodentium* burden at 10 d.p.i. (N). Mean $\pm$ SEM, $n = 4$. **(A-N)** Statistical significance was determined using unpaired two-tailed *t*-test or one-way ANOVA with Tukey’s post hoc test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.




Figure 5. *Lingo4*^{-/-} mice are more resistant to *S. Typhimurium* infection due to reduced IL-22-mediated pathology.

(A-B) Survival (A) and body weight change (B) of WT and *Lingo4*^{-/-} mice infected with *S. Typhimurium*, with or without streptomycin pre-treatment. *n* = 18–20; three experiments combined. (C) Fecal *S. Typhimurium* burden at 5 d.p.i., normalized to total *Eubacteria* 16S rRNA gene copies. Mean ± SEM, *n* = 4; representative of two experiments. (D-F) Representative H&E sections (D), histopathological score (E), and goblet cell frequency (F) at 5 d.p.i. Mean ± SEM, *n* = 4. Scale bars = 100 μm. (G-H) Numbers of neutrophils and inflammatory monocytes (G) and ILC3s (H) in siLP at 5 d.p.i. Mean ± SEM, *n* = 4–5; representative of two experiments. (I) Frequencies of IL-22⁺ ILC3s after IL-23 stimulation at 5 d.p.i. Mean ± SEM, *n* = 5. (J-L) Survival (J), body weight (K), and fecal *S. Typhimurium* burden (L) in WT and *Lingo4*^{-/-} mice treated with anti-IL-22 or rmIL-22 on days 0, 2, and 4 p.i. Mean ± SEM, *n* = 4. (A-L) Statistical significance was determined using unpaired two-tailed *t*-test or one-way ANOVA with Tukey's post hoc test. *, *p* < 0.05; **, *p* < 0.01; ***, *p* < 0.001; ****, *p* < 0.0001.




Figure 6. *Lingo4* is required to sustain mitochondrial function in ILC3s.

(A) Scheme: 293T cell were stably transfected with *Lingo4* having FLAG-tag was fused to its N-terminal part and 6xHis-tag to its C-terminal part. Flow cytometry histograms of surface and intracellular LINGO4 expression on 293T cells by anti-FLAG staining. Representative of three experiments. (B) Representative immunofluorescence image of FLAG-positive 293T-Lingo4 cells. Scale bar 5 μ m. Representative of three experiments. (C) Pathway analysis of proteins immunoprecipitated with anti-FLAG antibody from 293T-Lingo4 cells but not from 293T control cells (n=100; peptide coverage $\geq 10\%$). (D) Pathway

analysis of DEGs obtained by RNA-seq analysis of sort purified siLP ILC3 from WT and *Lingo4*^{-/-} mice. $n = 4$; $\text{padj} < 0.01$. **(E)** Representative TEM images of sort purified siLP ILC3 from WT and *Lingo4*^{-/-} mice. $n = 4$. Scale bars, 500 nm. **(F)** Representative flow cytometry plots and MFI of Mitotracker Green and Mitotracker Red staining in WT and *Lingo4*^{-/-} siLP ILC3 upon ex vivo stimulation. Mean $\pm$ SEM, $n = 3$; representative of two experiments. **(G)** Representative flow cytometry plots and frequency of mitoSOX⁺ siLP ILC3s from WT and *Lingo4*^{-/-} mice. Mean $\pm$ SEM, $n = 6$; two experiments combined. **(H)** Representative flow cytometry plots, frequency, and MFI of lipids staining by BODIPY 581/591 C11 in WT and *Lingo4*^{-/-} siLP ILC3s. Mean $\pm$ SEM, $n = 4$; representative of two experiments. **(I)** Representative flow cytometry plots, frequency, and MFI of pSTAT3⁺ siLP ILC3. Mean $\pm$ SEM, $n = 5$; representative of two experiments. **(J)** Representative flow cytometry plots and frequency of Annexin-V and 7AAD staining of siLP ILC3. Mean $\pm$ SEM, $n = 9$; three experiments combined. **(K)** Representative flow cytometry plots and frequency of Ki67 staining siLP ILC3. Mean $\pm$ SEM, $n = 4$; representative of two experiments. **(F-K)** Statistical significance was determined using unpaired two-tailed t -test or one-way ANOVA with Tukey's post hoc test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$.




Figure 7. Impaired ILC3 function is retained in *Lingo4^{ΔILC3}* mice.

(A) Frequency and MFI of mitoSOX⁺ siLP ILC3s from *Lingo4^{fl/fl}* and *Lingo4^{ΔILC3}* mice. Mean ± SEM, *n* = 8-9; two experiments combined. (B) Frequency of BODIPY 581/591 C11-positive cells and MFI in *Lingo4^{fl/fl}* and *Lingo4^{ΔILC3}* siLP ILC3s. Mean ± SEM, *n* = 8-9; two experiments combined. (C) Frequency and MFI of pSTAT3⁺ siLP ILC3. Mean ± SEM, *n* = 5. (D) Representative flow cytometry plots and frequency of Annexin-V and 7AAD staining of siLP ILC3. Mean ± SEM, *n* = 5. (E-F) Body weight variation (E) and fecal *C. rodentium* burden at 10 and 20 d.p.i. (F) of *Lingo4^{fl/fl}* and *Lingo4^{ΔILC3}* mice during *C. rodentium* infection. Mean ± SEM, *n* = 6. (G-I) Representative plots and absolute numbers of colonic ILC3s (G), ILC3 subsets (H), and cytokine production by colonic ILC3 at 10 d.p.i. Mean ± SEM, *n* = 4. ILC3s were defined as live lymphocyte-sized Lin⁻ (CD3⁻

CD19⁻ Thy1.2^{hi} CD45^{int} cells. **(A-I)** Statistical significance was determined using unpaired two-tailed *t*-test or one-way ANOVA with Tukey's post hoc test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$, ****, $p < 0.0001$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript